Stockwinners Market Radar for October 31, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:05 EDT Cathie Wood's ARK Investment bought 133.4K shares of PacBio today

19:12 EDT Blackstone exec sells $2.76M in common stock - In a regulatory filing, Blackstone disclosed that its General Counsel John Finley sold 29.9K shares of common stock on October 30th in a total transaction size of $2.76M.

18:26 EDT Bristol Myers names Christopher Boerner as Board Chair effective April 1, 2024 - Bristol Myers "announced that its Board of Directors has unanimously elected Christopher Boerner, Ph.D., to serve as Chair of the Board, effective April 1, 2024. He succeeds Giovanni Caforio, M.D., who will step down as Chair of the Board on April 1, 2024 and retire from the company after 23 years of service. Boerner was named Executive Vice President, Chief Operating Officer and CEO-elect on April 26 and, as of November 1, Boerner will be Chief Executive Officer of Bristol Myers Squibb."

18:21 EDT Omni Logistics files lawsuit against Forward Air to enforce merger pact - Omni Logistics announced that it has filed a complaint in the Delaware Court of Chancery against Forward Air Corporation regarding the companies' previously announced transaction. Omni's lawsuit seeks specific performance under the Agreement and Plan of Merger between Omni and Forward Air dated August 10, 2023, requiring Forward Air to comply with its obligations to complete the transaction. The complaint also seeks a judicial declaration confirming that Omni has complied with all required provisions of the Merger Agreement. Omni has requested a trial before the Court of Chancery to obtain a ruling enforcing the Merger Agreement prior to the Merger Agreement's outside expiration date of February 10, 2024.

18:01 EDT TransUnion director buys $102.5K in common stock - In a regulatory filing, TransUnion disclosed that its director Linda Zukauckas bought 2,350 shares of common stock on October 30th in a total transaction size of $102.5K.

17:54 EDT Novonix finalizes $100M grant award from U.S. DoE - NOVONIX "announced that its NOVONIX Anode Materials division finalized its $100M grant award from the U.S. Department of Energy to expand domestic production of high-performance, synthetic graphite anode materials at its Riverside facility in Chattanooga, Tennessee."

17:35 EDT SatixFy Communications announces completion of $60M transaction with MDA - SatixFy Communications announced the completion of the previously announced $60M transaction with MDA , a provider of advanced technology and services to the rapidly expanding global space industry. In line with the original agreement, MDA acquired SatixFy's digital payload division and UK subsidiary for $40M and paid an additional $20M in advanced payments under new commercial agreements (which includes the previous $10M advanced payment made in June to be applied to future orders of space grade chips. SatixFy continues to retain all its related ASIC intellectual property and new chips' development to support the growing market. The strategic transaction also establishes deep cooperation between SatixFy and MDA to utilize SatixFy's revolutionary digital payload chip-based technology for advanced digital satellite payloads and is expected to open up SatixFy's solutions to broader markets and new customers. The strategic transaction is in line with SatixFy's strategy to focus on being a top leading technology provider to satellite payload design companies, with its unique offering of multi-beam forming and beam-hopping, using its on-board-processing radiation-hardened chipsets.

17:30 EDT Tonix Pharmaceuticals trading resumes

17:20 EDT DraftKings announces agreeent with the Passamaquoddy Tribe - DraftKings announced it has reached an agreement in principle, subject to licensing and regulatory approvals, with the Passamaquoddy Tribe paving the way for the launch of its online sportsbook in Maine. The agreement between DraftKings and the Passamaquoddy Tribe will allow sports fans 21 years of age and older to access DraftKings' innovative, immersive and entertaining sportsbook app experience that includes a variety of wagering options including pre-match and in-game options as well as signature, built in-house same-game-parlay features. In response to the tragic events in Lewiston, ME on October 25, DraftKings will be donating $100,000 to Lewiston-Auburn Area Response Fund to support those affected. With Maine Community Foundation as a conduit, 100% of every dollar donated will be allocated to people impacted and the organizations that will help guide Lewiston-Auburn through the process of healing.

17:17 EDT Lockheed Martin awarded $177.05M Air Force contract - Lockheed Martin was awarded a $177.05M firm-fixed-price and a maximum amount to include a time and material ceiling amount of $100,000 on contract for F-16 Systems Program Office Foreign Military Sales support. This contract provides for Foreign Military Sales support to Chilean/Fuerza Aerea de Chile F-16 M6.6 Operational Flight Program and Systems Upgrade. Work is expected to be completed by November 30, 2032. This contract involves Foreign Military Sales to Chile. This contract was a sole source acquisition. The Air Force Life Cycle Management Center is the contracting activity.

17:15 EDT TSX approves Gran Tierra's notice of intention for a normal course issuer bid - Gran Tierra Energy announces that the Toronto Stock Exchange, or TSX, has approved its notice of intention to make a normal course issuer bid for its shares of common stock. As of October 20 there were 33,288,305 Shares issued and outstanding and the public float was 32,349,140 Shares. Pursuant to the Bid, Gran Tierra will be able to purchase for cancellation up to 3,234,914 Shares, representing 10% of the public float, at prevailing market prices at the time of purchase, through the facilities of the TSX, the NYSE American or alternative trading platforms in Canada or the United States, if eligible, or by such other means as may be permitted by the TSX, the NYSE and applicable securities laws for a one year period commencing on November 3, 2023 and ending on November 2, 2024. Gran Tierra has also entered into an Automatic Share Purchase Plan, or ASPP, in connection with the Bid. The brokerage firm conducting the Bid on behalf of Gran Tierra and administering the ASPP is Eight Capital. The ASPP is intended to allow for the purchase of Shares under the Bid when Gran Tierra would ordinarily not be permitted to purchase Shares due to regulatory restrictions and customary self-imposed blackout periods. Gran Tierra may purchase up to 14,306 Shares during any trading day, which represents approximately 25% of 57,225, which represents the average daily trading volume on the TSX for the most recently completed six calendar months prior to the TSX's acceptance of the notice of the Bid. Gran Tierra may effect repurchases from time to time in the open market.

17:03 EDT Tonix announces Phase 2 study of TNX-601 did not achieve significant results - Tonix Pharmaceuticals Holding announced topline results from the Phase 2 proof-of-concept double-blind, randomized, multi-center, placebo-controlled UPLIFT study of TNX-601 ER in patients with major depressive disorder, or MDD. The primary efficacy endpoint of change from baseline in depression severity, as measured by the Montgomery-Asberg Depression Rating Scale, or MADRS, total score, did not achieve clinical or statistical significance. "Based on these efficacy results, we are discontinuing development of TNX-601 ER. We look forward to topline results from our Phase 2 study of TNX-1900 in chronic migraine in early December and topline results from our Phase 3 potential NDA-enabling study of TNX-102 SL in fibromyalgia in late December," said Seth Lederman, President and CEO. In the Phase 2 UPLIFT study, TNX-601 ER was orally administered as monotherapy once a day to 132 patients who, upon entering the study, met a DSM-5 diagnosis of moderate-to-severe depression with a duration for the current major depressive episode of at least 12 weeks. Efficacy was assessed using the MADRS to measure any potential change in patients' depression severity from baseline. In the study, TNX-601 ER was generally well-tolerated with a favorable safety profile. There was one serious adverse event experienced in the placebo group, and two SAEs in the active treatment group deemed possibly related to study drug, both of which resolved without sequelae.

16:59 EDT Yum China falls 10% to $47.00 after Q3 results miss estimates

16:55 EDT Tonix Pharmaceuticals trading halted, news pending

16:47 EDT Match, Google reach binding term sheet for settlement - The Match (MTCH) plaintiffs and Google (GOOG) informed the court that they have reached a binding term sheet for a settlement of their respective claims against each other in the Match Group, LLC et al vs. Google LLC et al lawsuit. Under the terms, the $40 million placed in escrow will be returned to Match Group and no other amounts will be owed by the Match plaintiffs to Google relating to the claims in the lawsuit for the period ending December 31, 2023. The parties have agreed that by March 31, 2024 Match Group's apps will implement Google's User Choice Billing pursuant to which Match Group brands will pay standard rates of 15% on subscriptions and 30% on a la carte transactions for in-app transactions processed through Google's payment system and 11% on subscriptions and 26% on a la carte transactions for in-app transactions processed through our payment systems. The parties will enter a new partnership agreement that will provide value exchange across their broad relationship, which we expect will essentially offset the additional costs that Match Group brands expect to incur over the three years starting in 2024 associated with the implementation and continued use of User Choice Billing in compliance with Google's payment policy during that period.

16:40 EDT Novavax's Nuvaxovid XBB.1.5 dispersion receives approval in Europe - Novavax announced the European Commission has granted approval for Nuvaxovid XBB.1.5 dispersion for injection COVID-19 Vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older. This decision follows positive opinion for approval from the Committee for Medicinal Products for Human Use of the European Medicines Agency. Novavax is working closely with EU member states that have requested doses through the advance purchase agreement to confirm timing of dose delivery on a country-by-country basis. Approval was based on non-clinical data showing that Novavax's updated COVID-19 vaccine induced functional immune responses against XBB.1.5, XBB.1.16 and XBB.2.3 variants. Additional non-clinical data demonstrated that Novavax's vaccine induced neutralizing antibody responses to newly emerging subvariants BA.2.86, EG.5.1 FL.1.5.1 and XBB.1.16.6 as well as CD4+ polyfunctional cellular responses against EG.5.1 and XBB.1.16.6. These data indicate Novavax's vaccine can stimulate both arms of the immune system and may induce a broad response against circulating variants. Novavax's vaccine is authorized for use in the U.S. and is currently under review in other markets.

16:32 EDT Yum China reports Q3 SSS up 4% - Same-store sales increased 4% year over year, with increases of 4% at KFC and 2% at Pizza Hut in constant currency. Opened 500 net new stores during the quarter; total store count reached 14,102, as of September 30, 2023. Total system sales increased 15% year over year, with increases of 15% at KFC and 13% at Pizza Hut in constant currency. Growth was mainly attributable to new unit contribution, same-store sales and lapping of temporary closures in the prior year. Restaurant margin was 17.0%, compared with 18.8% in the prior year period, mainly due to lapping of austerity measures and temporary relief in the prior year.

16:28 EDT AutoNation launches AutoNationParts.com - AutoNation announced the official launch of AutoNationParts.com, a new eCommerce website enabling Customers to purchase high-quality automotive parts and accessories at competitive prices, shipped directly to their homes. Providing fast nationwide shipping for guaranteed-to-fit genuine manufacturer parts from more than 25 brands, AutoNationParts.com aims to meet growing demand from DIY mechanics and "do-it-for-me" Customers who can confidently purchase parts online and have them expertly installed by their chosen mechanic, ensuring a seamless and convenient experience.

16:23 EDT Tabula Rasa HealthCare stockholders approve acquisition by Nautic Partners - Tabula Rasa HealthCare announced that its stockholders approved the previously announced acquisition by Nautic Partners, following which TRHC is expected to combine with ExactCare Pharmacy, a portfolio company of Nautic. The proposal to adopt the merger agreement was approved at a virtual special meeting of the Company's stockholders held today with approximately 99.6% of the votes cast in favor of the proposal, which represented approximately 70.9% of the outstanding shares of Company common stock. The Company expects to complete the transaction during the Q4, subject to customary closing conditions. Upon closing, Tabula Rasa will become a privately held company and shares of TRHC common stock will no longer be listed on the Nasdaq stock exchange.

16:22 EDT Unum Group announces $500M share repurchase authorization - Unum Group announced that its board of directors has approved a share repurchase program authorizing the company to repurchase up to $500M of its common stock from time to time beginning on January 1, 2024. This program follows the company's current share repurchase program, which expires on December 31, 2023.

16:19 EDT Oneok raises FY23 guidance - The company increased its 2023 net income and adjusted EBITDA guidance midpoints by $120M and $125M, respectively, on a ONEOK pre-acquisition basis to be comparable with the previous guidance provided on August 7.

16:17 EDT Standard Lithium exercises option agreement on South West Arkansas project - Standard Lithium announced the exercise of its option agreement with TETRA Technologies, for the South West Arkansas SWA Project. This significant move affirms the Company's strategic direction, and builds on the positive insights garnered from the recent Preliminary Feasibility Study PFS . "This is an important and natural step for us as we advance our South West Arkansas Project," said Andy Robinson, President and COO of Standard Lithium. ...The Agreement entered into with TETRA in 2017 granted the Company the exclusive option, exercisable over a ten-year period, to the brine production rights on approximately 27,000 net acres of brine leases located in Columbia and Lafayette Counties, Arkansas. Exploration activities on the brine leases commenced in 2018 to identify the presence of lithium-bearing brines, and shortly thereafter, the Company announced a maiden inferred mineral resource of 802,000 tonnes lithium carbonate equivalent at an average lithium concentration of 199 mg/L from the area now known as the SWA Project.

16:13 EDT Noble Corp. sees FY23 adjusted EBITDA $775M-$825M, - Representing the top half of the previous range.

16:12 EDT Selecta eligible for up to $615M in remaining SEL-212 payments, royalties - In connection with this transition, 15 Selecta employees currently supporting ImmTOR manufacturing and clinical development activities for SEL-212 are expected to become employees of Sobi. In addition, Peter G. Traber, M.D., Chief Medical Officer of Selecta, will begin serving as a consultant to Sobi, helping to oversee the clinical and regulatory activities associated with SEL-212. Dr. Traber will also continue to serve in his role as Chief Medical Officer at Selecta on a part-time basis. "We believe transitioning our manufacturing operations to Sobi will further streamline our organization, consistent with our announced strategic objective to optimize the value of our SEL-212 royalty stream for stockholders," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta. "Leveraging ImmTOR, the only immune tolerance platform with positive Phase 3 data, we firmly believe that SEL-212 has strong potential to address this significant unmet need and exceed $700 million in peak sales in the U.S." Sobi licensed SEL-212 from Selecta in June 2020 and is responsible for development, regulatory and commercial activities in all markets outside of China. Selecta was originally responsible for ImmTOR manufacturing. Selecta is eligible to receive up to $615M in remaining regulatory and commercial milestone payments and tiered double-digit royalties on net sales of SEL-212.

16:08 EDT RBB Bancorp names Rizkalla deputy chief risk officer, resumes share repurchases - RBB Bancorp announced the appointment of Mina Rizkalla as SVP/Sr. BSA Officer and Deputy Chief Risk Officer of RBB Bancorp and its wholly-owned bank subsidiary, Royal Business Bank. Rizkalla will be the head of the Bank's Bank Secrecy Act department where he will oversee the Bank's Anti-Money Laundering/Countering the Financing of Terrorism compliance program and assist in the administration of the Bank's comprehensive risk management programs for assessing, identifying, monitoring, and reducing risks. Rizkalla was previously the EVP & Chief Risk Officer/BSA Officer of Commonwealth Business Bank, which he joined in 2021. He brings significant experience in BSA/AML compliance, including his management of the BSA and compliance departments at CTBC Bank, East West Bank and OneWest Bank. He graduated from California State University, Los Angeles with a Bachelor of Science in Criminology. The Company also announced that it will resume repurchasing shares of its common stock under a 10b5-1 trading plan. The plan is part of the Company's previously announced one million share repurchase program under which approximately 433,000 shares remain available and authorized for repurchase.

16:08 EDT Selecta in pact to shift ImmTOR for SEL-212 rights and clinical ops to Sobi - Selecta Biosciences announced that it has entered into an agreement to transition the manufacturing and development rights and remaining clinical operations of ImmTOR for SEL-212 to its development and commercialization partner, Swedish Orphan Biovitrum or Sobi. As of November 6 Sobi will assume responsibility for the manufacturing and commercial supply of ImmTOR for SEL-212. SEL-212, a combination of Selecta's ImmTOR immune tolerance platform and a therapeutic uricase enzyme pegadricase is in development for the treatment of chronic refractory gout. A Biologics License Application BLA submission for SEL-212 remains on track for the first half of 2024..."Leveraging ImmTOR, the only immune tolerance platform with positive Phase 3 data, we firmly believe that SEL-212 has strong potential to address this significant unmet need and exceed $700M in peak sales in the U.S." Sobi licensed SEL-212 from Selecta in June 2020 and is responsible for development, regulatory and commercial activities in all markets outside of China. Selecta was originally responsible for ImmTOR manufacturing. Selecta is eligible to receive up to $615M in remaining regulatory and commercial milestone payments and tiered double-digit royalties on net sales of SEL-212.

16:05 EDT Marchex names Holly Aglio as CFO - Marchex "announced that Holly Aglio has joined the company as Chief Financial Officer. Aglio is a seasoned financial leader, having served in multiple influential financial management roles during her career, and will lead Marchex's finance and accounting organizations."

16:02 EDT Chesapeake, Vitol enter Heads of Agreement - Chesapeake Energy and Vitol announced the entrance into a Heads of Agreement with Chesapeake Energy Marketing L.L.C. a subsidiary of Chesapeake Energy Corporation. Under the HOA, Chesapeake will supply up to 1M tonnes of LNG per annum to Vitol with the purchase price indexed to Japan Korea Marker for a period of 15 years. Following the execution of the HOA, Chesapeake and Vitol will jointly select the most optimal liquefaction facility in the United States to liquify the gas produced by Chesapeake for delivery to Vitol. The HOA has a targeted start date in 2028.

15:16 EDT OmniLit Acquisition Corp. shareholders approve merger with Syntec Optics - OmniLit Acquisition Corp. announced that its shareholders voted to approve the previously announced business combination with Syntec Optics at OLIT's Annual meeting of shareholders held October 31. Over 99.9% of the votes cast at the Annual Meeting for the Business Combination Proposal were cast in favor. OLIT shareholders also voted to approve all other proposals presented at the Annual Meeting.

14:19 EDT WEC Energy projects complete exit from coal by the end of 2032 - Says remains on track for "strong" 2023. Comments taken from Q3 earnings conference call.

13:35 EDT PriceSmart says recently decided to raise membership fee by $5 in most markets - PriceSmart CFO Michael McCleary stated during the company's Q4 earnings call: "Following many years where our annual membership fee for 2 cards has been $35 in most markets, $75 for platinum, we recently decided to raise our fee by $5 in most markets for all membership types. We expect these fee increases to take place on a staggered basis in most countries during fiscal year 2024."

13:01 EDT Novavax announces positive CHMP opinion for updated COVID vaccine - Novavax announced that the Nuvaxovid XBB.1.5 dispersion for injection COVID-19 Vaccine has been recommended for approval for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older in the European Union by the Committee for Medicinal Products for Human Use of the European Medicines Agency. The European Commission will review the CHMP recommendation and is expected to make a final decision in the coming days, the company said in a statement. "Following the positive CHMP opinion and pending European Commission decision, Novavax will work closely with EU member states on our shared goal of delivering an updated protein-based non-mRNA COVID-19 vaccine in Europe," said John Jacobs, CEO of Novavax.

12:48 EDT Data Knights Acquisition Corp trading resumes

12:43 EDT Data Knights Acquisition Corp trading halted, volatility trading pause

12:36 EDT American Acquisition Opportunity Inc trading resumes

12:31 EDT American Acquisition Opportunity Inc trading halted, volatility trading pause

12:01 EDT Tetra Technologies falls -14.5% - Tetra Technologies is down -14.5%, or -81c to $4.77.

12:00 EDT Catalent falls -16.9% - Catalent is down -16.9%, or -$6.75 to $33.16.

12:00 EDT Shutterstock rises 20.8% - Shutterstock is up 20.8%, or $7.13 to $41.45.

11:56 EDT Cytokinetics trading resumes

11:41 EDT Dominion's CVOW project receives favorable BOEM Record of Decision - Dominion Energy's Coastal Virginia Offshore Wind received a favorable Record of Decision from the Bureau of Ocean Energy Management. The project is on-time and on budget with onshore construction commencing later this year. This is the last major milestone before BOEM approves the Construction and Operations Plan, which authorizes construction to begin offshore. The 2.6-gigawatt CVOW project will generate enough clean, renewable energy to power up to 660,000 homes once fully constructed in late 2026 and satisfy the mandates the 2020 Virginia Clean Economy Act. CVOW is expected to generate fuel savings of $3 billion for customers during the project's first 10 years of operation.

11:23 EDT Evaxion Biotech announces initial Phase 2 data on EVX-01 vaccine - Evaxion Biotech announced initial results from the EVX-01 Phase 2 clinical trial, confirming previous Phase 1 findings. A comprehensive clinical update will be presented at the Society for Immunotherapy of Cancer 38th annual meeting, taking place in San Diego, California, from November 1-5, 2023. Key highlights of the initial Phase 2 results for the first five metastatic melanoma patients treated with EVX-01 include: Phase 2 data confirm the favorable safety profile of EVX-01 observed in the Phase 1 trial; Promising immunological and clinical outcomes align with the Phase 1 outcomes; Upon EVX-01 treatment, a pronounced and ongoing tumor reduction was observed in a patient with progressive disease; Phase 2 data confirms Evaxion's AI-Immunology platform's ability to identify therapeutically relevant cancer vaccine targets.

11:18 EDT ShiftPixy trading halted, volatility trading pause

11:03 EDT Ford says F-150 Lightning to launch to Switzerland this year - The Ford F-150 Lightning is coming to Switzerland in limited numbers this year, announced Ford. "It's the second European market for the truck following the April announcement that F-150 Lightning is coming to Norway. With its planned launch set for the end of November, F-150 Lightning will prove the electric truck is at home not only in cities, but also in the middle of nature and on the challenging roads of the Alps. The Ford F-150 Lightning can be ordered from November and costs 127,000 Swiss francs," the company stated. Reference Link

10:49 EDT JetBlue sees Q1 capacity 'slightly down' y/y

10:46 EDT Buyer consortium calls Hollysys' statements 'misleading and alarming' - Buyer consortium led by Recco Control Technology and Dazheng Group issued a statement regarding Hollysys Automation Technologies' update on its ongoing sale process and the shareholder request for a special meeting. Members of the consortium also include TFI Asset Management Limited, and Great Wall Capital Co., Ltd, who have entered into a memorandum of strategic cooperation with Recco Control Technology and Dazheng Group in connection with the proposed acquisition of Hollysys. Hollysys' statement on October 30, 2023, suggested that more than 30% of registered shareholders, as of the demand record date previously set by the board of Hollysys, have validly submitted a request for a special meeting. Despite the valid request from shareholders representing significant ownership in the Company, Hollysys has to date refused to call a special meeting. The Hong Kong action referred to in Hollysys' statement, which is founded on unproven allegations, has been brought by a group of senior employees of Hollysys Group Companies, Dr Changli Wang, the CEO, Chief Strategy Officer and a director of Hollysys, and Plus View Investments Limited against Ace Lead Investments Limited, a registered shareholder of Hollysys and Mr. Shao Baiqing seek an injunction preventing the board of Hollysys acting on the request for a special meeting served by Ace Lead Investments Limited. Despite having suggested in their October 30 statement that more than 30% of registered shareholders have requested for a special meeting, the board of Hollysys has now indicated, conveniently after the Company's own founder and senior management had brought an action in a Hong Kong court, to injunct the special meeting. It will only consider whether or not to call a special meeting after November 21, 2023, when the application is scheduled to be heard, and the Court has made its determination of that action. There is no certainty when the Court's determination will be delivered and no account is taken of the possibility of an appeal by the unsuccessful party which could significantly delay the final determination of the application. It is impossible to predict when, if ever, the board of Hollysys will consider the request for a special meeting. This is prejudicing the rights and interests of all the shareholders who have requested the special meeting who hold more than 30% of the Company. Under British Virgin Islands law, the Hong Kong action is irrelevant to the obligations of the board of Hollysys to properly consider, in a timely manner, convening the special meeting which more than 30% of the shareholders requested as long ago as August 24, 2023. In light of the totality of the circumstances, the Board's declaration that it will not act on the special meeting until a foreign court in Hong Kong has made final determination in a lawsuit brought by the Company's own senior management amounts to nothing more than a concerted effort to frustrate the shareholders' legitimate exercise of their fundamental right to have a special meeting convened. The right of shareholders to meet is fundamental and unqualified. The consortium calls on the board of Hollysys to respect the rights of its shareholders and convene the special meeting immediately. There is no legitimate reason for further delay by the Board.

10:39 EDT LoanDepot provides down payment alternative with 'accessZERO' program - loanDepot has launched its new "accessZERO" program that it says is intended to make homeownership more accessible for aspiring homebuyers grappling with traditional down payment requirements, high-interest rates and rising home prices. "With affordability concerns eroding consumers' purchasing power, accessZERO is a powerful option that offers financial flexibility by providing an alternative to one of the barriers to homeownership," the company said in a statement. "As we continue to unlock new ways for our customers to purchase homes in today's challenging market, accessZERO helps address a significant barrier, particularly for first-time buyers grappling with the obstacle of saving for the higher-down payments that come with the rising costs of housing," said LDI Mortgage President Jeff Walsh.

10:19 EDT JetBlue sees up to 6 aircrafts grounded due to GTF engine issues

10:13 EDT JetBlue sees 5%-7% capacity growth for FY23

10:10 EDT TikTok announces new integration for advertisers using Salesforce Marketing Cloud - TikTok has unveiled a new lead generation integration for Salesforce Marketing Cloud. This integration introduces a no-code solution that enables TikTok advertisers to transfer their leads directly to Salesforce Marketing Cloud. TikTok Lead Generation is the next-gen solution for capturing leads from an audience that's tuned in to discover, search, and connect on TikTok. This new integration will be available on AppExchange, Salesforce's leading enterprise cloud marketplace, for businesses using Salesforce Marketing Cloud. With this new app, leads captured on TikTok will be synced to Salesforce Marketing Cloud in real time, eliminating the time and effort required to manually download leads. When a lead is generated on TikTok, sales and marketing teams will be able to instantly access leads in Salesforce Marketing Cloud, allowing for prompt follow-up and personalized engagement. This quick response should enhance the chances of turning leads into loyal customers.

10:04 EDT JetBlue says 'not commenting' on Spirit beyond what is in prepared remarks - Comments taken from Q3 earnings conference call.

10:03 EDT Epam Systems signs strategic collaboration agreement with AWS - EPAM Systems (EPAM) announced a Strategic Collaboration Agreement with Amazon Web Services (AMZN) to help enterprises solve complex business challenges, drive growth, and scale innovation through cutting-edge cloud solutions, services, and strategies. The agreement will focus on accelerating modernization, adopting cloud-native architecture, and leveraging artificial intelligence and advanced analytics to create customer value in key industries, including healthcare, life sciences, financial services, insurance, energy and gaming, EPAM said. "We're excited to expand our work with AWS to help our clients transform into adaptive, cloud-native organizations and stay competitive in a quickly evolving digital landscape," said Elaina Shekhter, Chief Marketing and Strategy Officer at EPAM.

10:00 EDT Tetra Technologies falls -14.8% - Tetra Technologies is down -14.8%, or -83c to $4.75.

10:00 EDT Annovis Bio falls -19.1% - Annovis Bio is down -19.1%, or -$1.56 to $6.59.

10:00 EDT Shutterstock rises 14.7% - Shutterstock is up 14.7%, or $5.04 to $39.35.

09:59 EDT Sysco expects to maintain a net debt to adjusted EBITDA ratio of 2.50-2.75x. - Says committed to dividend aristocrat status. Expects to return approx. $1.75B back to shareholders in 2024. Comments taken from Q1 conference call presentation slides.

09:56 EDT JetBlue sees ATC challenges in northeast dissipating in winter

09:47 EDT Tetra Technologies falls -10.2% - Tetra Technologies is down -10.2%, or -57c to $5.01.

09:47 EDT Annovis Bio falls -16.3% - Annovis Bio is down -16.3%, or -$1.33 to $6.82.

09:47 EDT Shutterstock rises 15.5% - Shutterstock is up 15.5%, or $5.32 to $39.63.

09:40 EDT Knightscope expands contract with retail client, enters contract with university - Knightscope announces the expansion of an existing retail client and a new contract with a university in Alaska. In order to protect employee safety and deter theft and illegal trespassing at its loading docks, an online retailer with four U.S. warehouses that sells over 40,000 authentic, brand-name fragrances, skincare, makeup, haircare, aromatherapy, and candles signed an agreement for an additional 2 K1 Hemispheres for its second location. Proposals for its New York and Nevada locations were subsequently requested and submitted. A university in Alaska elected to retrofit a competitor's legacy blue light emergency communications system with Knightscope's K1 Retrofit Kit. The K1 Retrofit Kit allows users to upgrade other manufacturer's blue-light-style phones and call boxes so that they function like Knightscope's Emergency Phone Products with features like wireless solar power, wireless phone connectivity, and self-monitoring software. There are 50 more units available for upgrade throughout the campus assuming success of the first.

09:34 EDT Nevada reports September statewide gaming win up 1.69% to $1.27B - Nevada reports September Las Vegas Strip gaming win up 2.79% versus last year to $741.23M. Publicly traded companies in the casino gaming and gambling space include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (PDYPY), Gan Limited (GAN), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn Entertainment (PENN), William Hill (WIMHY) and Wynn Resorts (WYNN).

09:32 EDT American Securities to sell Paragon Medical to Ametek for $1.9B in cash - American Securities announced that it has entered into a definitive agreement to sell Paragon Medical to Ametek in an all-cash transaction valued at approximately $1.9B. The transaction is subject to customary closing conditions, including applicable regulatory approvals. Founded in 1991 and based in Pierceton, Indiana, Paragon provides a diverse, industry-leading product portfolio of world-class solutions to blue-chip and emerging original equipment manufacturers across diverse medical end markets.

09:30 EDT Carisma Therapeutics to present efficacy results of Moderna collaboration - Carisma Therapeutics (CARM) will present new findings at the Society for Immunotherapy of Cancer Annual Meeting regarding its first-of-its-kind collaboration with Moderna (MRNA). The collaboration aims to bring together Carisma's chimeric antigen receptor macrophage - CAR-M - platform with Moderna's mRNA and lipid nanoparticle technologies to generate and develop in vivo CAR-M therapeutics. The late-breaking presentation demonstrates Carisma's CAR-M therapy can be directly produced in vivo, or within the body, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP. The pre-clinical data demonstrate feasibility, tolerability, and efficacy against metastatic solid tumors. This novel approach to cancer immunotherapy offers an off-the-shelf solution that has the potential to increase access to CAR-based therapies and will be the basis of CAR-M programs to be developed under the Carisma and Moderna collaboration.

09:23 EDT Sprouts Farmers Market appoints Curtis Valentine as chief financial officer - Sprouts Farmers Market announced the appointment of Curtis Valentine as chief financial officer of the company, effective January 1, 2024. Valentine is currently Sprouts' senior vice president of finance and will succeed Lawrence Molloy, who previously announced his intention to retire as chief financial officer at the end of 2023.

09:20 EDT Sigma Lithium receives 50% prepayment from Glencore for lithium shipment - Sigma Lithium (SGML) has received from Glencore (GLNCY) the prepayment for its third shipment of Triple Zero Green Lithium, totaling 20,000 tons. The 50% prepayment reflects a premium pricing at a 9% provisional price of lithium hydroxide at LME for the company's Triple Zero Green Lithium. The shipment is part of a commercial distribution and marketing agreement with Glencore. In addition to the prepayment received from Glencore, the Company has access to trade finance green credit lines from both Santander and XP that can be drawn down upon delivery of its triple Zero Green Lithium to the Vitoria Port warehouses managed by Multilift. ACC/ ACEs are customary commercial banking trade finance in Brazil provided by commercial banks to exporters with counterparty clients with robust creditworthiness. Glencore is the counterparty client for Sigma Lithium in the third shipment.

09:17 EDT Qualys' cybersecurity products available in Amazon's AWS Marketplace - Qualys (QLYS) announced the availability of its VMDR TruRisk, FixIT and ProtectIT capabilities in Amazon's (AMZN) AWS Marketplace priced and packaged for small-to-medium sized businesses and small-to-medium enterprises. AWS Marketplace is a digital catalog with thousands of software listings from independent software vendors that makes it easy to find, test, buy and deploy software that runs on Amazon Web Services - AWS -. The Qualys offering aims to reduce cyber risk across infrastructure. The package includes vulnerability, patch and Endpoint Detection and Response capabilities. Additionally, Qualys leverages AWS services such as Amazon Elastic Compute Cloud, AWS Lambda, and Amazon Simple Storage Service.

09:14 EDT Micron announces availability of Crucial T500 Gen4 NVMe SSD - Micron Technology announced the availability of the Crucial T500 Gen4 NVMe SSD as an expansion of its NVMe solid-state drive portfolio. The Crucial T500 SSD is a PCIe 4.0 NVMe drive, which leverages Micron's advanced 232-layer 3D NAND technology with industry-leading NAND I/O speeds of 2.4 gigabytes per second and is engineered to improve performance for console and PC gamers, photo and video editors and content creators. Available in two options, the T500 SSD with the heatsink is specifically designed for platforms like the PlayStation 5 and PC gaming rigs, while the version without the heatsink fits well in laptops, desktops and workstations.

09:13 EDT Senti Bio announces multiple data presentations at SITC meeting - Senti Biosciences announced four poster presentations at the Society for Immunotherapy of Cancer, SITC, Annual Meeting, being held November 1-5, 2023, in San Diego, CA. "This continues to be a definitive year for Senti with multiple presentations across multiple medical and scientific venues," said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. "The four posters at this year's SITC meeting highlight the breadth and modularity of our platform. We also continue to make progress with our longstanding partner BlueRock, as highlighted by our two joint posters. Overall, I am pleased with the growing interest in our Gene Circuit platform throughout the global scientific community as we soon embark on using these technologies in the clinic."

09:13 EDT Iovance Biotherapeutics to present clinical, preclinical data for TIL therapies - Iovance Biotherapeutics announced the publication of abstracts for poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte, TIL, therapies at the Society for Immunotherapy of Cancer's, SITC, 38th Annual Meeting in San Diego, CA, November 1-5, 2023. An abstract on the four-year analysis of pooled Cohorts 2 and 4 of the C-144-01 trial reports the longest follow-up data on lifileucel treatment outcomes in the largest population of patients with anti-PD-1-refractory advanced melanoma treated with TIL therapy. As of the data cutoff date of June 16, 2023, median C-144-01 trial follow-up was 48.1 months in heavily pretreated patients with advanced melanoma. One-time lifileucel TIL therapy demonstrated durable efficacy with a four-year OS rate of 22.2%. The longest response was ongoing at 59.9 months. Treatment-emergent adverse events were consistent with known safety profiles of lymphodepletion and IL-2, and their incidence decreased over time. The four-year analysis further supports the use of lifileucel as a potential treatment option in these patients that is differentiated from other immunotherapies.

09:12 EDT Indaptus to present interim data of first cohort in trial of INDP-D101 - Indaptus Therapeutics announces it will be presenting interim data from the first cohort of four patients in the Phase 1 INDP-D101 trial of its lead compound, Decoy20. The interim data, released in abstract form, demonstrated that as of August 31, 2023, each of the first cohort participants experienced transient activation of biomarkers associated with innate and/or adaptive immune responses, and generally expected transient adverse events, both associated with predicted rapid clearance of Decoy20. The data in full will be presented in a poster at the Society for Immunotherapy of Cancer, SITC, on November 4. The conference will be held from November 1-5, 2023 in San Diego. Michael Newman, Ph.D., Indaptus' Founder and Chief Scientific Officer noted, "Even in this early study, Decoy20 is exceeding our expectations from the perspective that we are seeing activation of the immune system, based on transient expression of multiple plasma cytokines and chemokines, with expected transient adverse events. These results, in conjunction with the desired and observed rapid clearance of Decoy20 from the blood, are highly supportive of our "Pulse-Prime" hypothesis for the Decoy20 mechanism of action." The abstract/poster is titled, "Preliminary results of an in progress, first-in-human Phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors." First cohort patients received a single dose of 7x107 killed Decoy20 bacteria via a one-hour IV infusion. As of August 31, 2023, treatment-related adverse events, potentially expected based upon prior clinical studies with purified lipopolysaccharide, have included, among other events, changes in hemodynamic parameters, transaminase elevations, and lymphopenia; all resolved with or without treatment within 30 minutes to 3 days. The Company believes the short half-life of Decoy20 observed in blood coupled with the marked, but transient, induction of multiple cytokines and chemokines over approximately 24 hours supports the PK "pulse" and PD "prime" hypothesis for the Decoy20 immune-oncology strategy.

09:10 EDT Riverside signs agreement to sell Energy Exemplar to Blackstone, Vista Equity - The Riverside Company has signed a definitive agreement to sell Energy Exemplar, EE, a leading simulation software provider for the global power market, to private equity funds affiliated with Blackstone and Vista Equity Partners. Financial details were not disclosed. "We're incredibly proud of our partnership and accomplishments with Energy Exemplar over the past six years," said RAF Managing Partner Simon Feiglin. "During our partnership with EE's Founder Glenn Drayton, we recruited CEO David Wilson and built an effective international management team and grew the employee base by 7x. We also scaled a small Adelaide-based software business into 79 countries with major offices in India, United Kingdom, North America and Singapore by establishing a global presence in sales, marketing, customer support and product development."

09:09 EDT Smokey Bones partners with celebrity chef Robert Irvine - Smokey Bones announces that world-class culinary personality and philanthropist, Chef Robert Irvine, will join the Masters of Meat to introduce a limited-time menu, Robert's Ribfeast, starting on October 31, 2023. Fans are asked to bring their appetites to try this delicious new menu, which will benefit the Robert Irvine Foundation, dedicated to transforming the lives of service members, veterans, first responders and their families. Smokey Bones has committed to donate 10 percent of sales from "Robert's Ribfeast" promotion, up to $100,000. As a Smokey Bones fan and loyalist, particularly of its award-winning ribs, Chef Irvine is working with the brand to share good food with guests while supporting and showing appreciation for the country's military and veterans.

09:08 EDT Cardio Diagnostics gets contract from Vizient for heart disease tests, no terms - Cardio Diagnostics Holdings announced its AI-driven molecular heart disease tests, which identify objective epigenetic and genetic biomarkers in patients suspected to be at risk or who may have coronary heart disease, has received an Innovation Technology contract from Vizient ..The contract, which will be effective November 1, was awarded by Vizient based on a recommendation from its council of hospital experts, and it signifies to Vizient hospital and health system customers unique qualities that potentially bring improvement to the healthcare industry..."We are honored to receive this contract from Vizient, which will accelerate access to our novel heart disease tests that leverage AI and a precision medicine approach," said Cardio Diagnostics CEO Meesha Dogan, PhD., who is also the co-inventor of the technology behind Cardio Diagnostics. "This contract recognizes our mission to transform cardiovascular disease management through advanced diagnostics. Our team is excited to make cardiovascular care more accessible across the country through this contract."

09:07 EDT Akoya Biosciences to showcase spatial biology 2.0 solutions - Akoya Biosciences will be showcasing its latest Spatial Biology 2.0 solutions and ultrahigh-plex spatial phenotyping data at the Society for Immunotherapy of Cancer 38th Annual Meeting, being held in San Diego, California, November 1-5, 2023. At booth #719, Akoya Biosciences will highlight its new PhenoCycler-Fusion 2.0 and PhenoImager HT 2.0 platforms, which offer significant advancements in speed and scale for spatial biology research. PhenoCycler-Fusion 2.0: Features multi-slide automation, enabling researchers to generate ultrahigh-plex spatial phenotyping data for larger and more complex samples at unprecedented speed. PhenoImager HT 2.0: Features onboard spectral unmixing, which accelerates biomarker development and validation workflows. Among the posters being presented at SITC is one describing the spatial tumor microenvironment landscapes of cutaneous squamous cell carcinoma tissues from patients over the course of immunotherapy treatment. An ultrahigh-plex antibody panel encompassing cell lineages, activation states, immune checkpoints, structural and metabolic markers was deployed on the PhenoCycler-Fusion platform for analysis of the tissue microenvironment. Cellular phenotypes, spatial neighborhoods and functional states driving tumor pathogenesis and response to immunotherapy were identified. The poster will be presented by Arutha Kulasinghe, Ph.D., leader of the Clinical-oMx Group at the Frazer Institute of the University of Queensland, Australia, and founding scientific director of the Queensland Spatial Biology Centre. Dr. Kulasinghe, his colleagues, and Akoya collaborators recently published a peer-reviewed article describing another ultrahigh-plex spatial biology study that revealed a high degree of intra-tumoral heterogeneity and distinct immune microenvironments in a tumor tissue section from a head and neck squamous cell carcinoma patient with a partial response to treatment with an immune checkpoint inhibitor. These studies reinforce the value of single-cell ultrahigh-plex spatial phenotyping as a powerful tool for defining spatial tissue signatures associated with therapy response and resistance. Fourteen of Akoya's eighteen qualified CRO service providers will also be exhibiting at SITC. Akoya's CRO network continues to grow rapidly, reflecting the demand for spatial phenotyping solutions across the biopharmaceutical industry. Offering biomarker testing services, these CROs enable drug developers and academic research institutions to accelerate the discovery and development of new immuno-therapies.

09:06 EDT Werewolf Therapeutics to present clinical, preclinical data at SITC meeting - Werewolf Therapeutics announced that a poster describing interim first-in-human clinical results from initial monotherapy dose-escalation cohorts in the ongoing Phase 1/1b study of WTX-124 will be presented at the Society for Immunotherapy of Cancer's, SITC, 38th Annual Meeting, taking place November 1-5, 2023 in San Diego, California. Additional posters with preclinical data supporting the PREDATOR platform and INDUKINE product candidates will also be presented at the meeting. "At SITC, we look forward to sharing first-in-human clinical results from our lead candidate, WTX-124, including initial assessments of safety, pharmacokinetics, relevant biomarkers and preliminary antitumor activity from the ongoing monotherapy dose-escalation portion of our Phase 1/1b study in solid tumors. These data will provide early insight into the profile of WTX-124 and preferential activation through our INDUKINE design, including additional data since the abstract submission in June," said Randi Isaacs, M.D., Chief Medical Officer of Werewolf. "Several preclinical abstracts were also accepted for poster presentation, collectively reinforcing distinct immune activating potential of our INDUKINE molecules across various mechanisms, including IL-2, and as a complement to other anti-cancer approaches, including checkpoint inhibitors and cell therapy."

09:05 EDT Tetra Tech awarded $800M task order contract for PFAS remediation - Tetra Tech announced that the U.S. Army Engineering Support Center, Huntsville, has selected the Company for a multiple-award, five-year, $800M indefinite delivery, indefinite quantity contract to remove and replace aqueous film forming foam, AFFF, containing per- and poly-fluoroalkyl substances ,PFAS, from fire suppression systems at installations throughout the United States... "Tetra Tech has supported the U.S. Department of Defense for decades to safely address potentially harmful chemicals at its bases and in the surrounding environment," said Dan Batrack, Tetra Tech Chairman and CEO. "We look forward to using our Leading with Science approach to support the proactive removal and replacement of AFFF containing PFAS in firefighting systems, keeping our servicemembers safe and preventing future environmental contamination and cleanup."

09:05 EDT BioLineRx enters license agreement with GloriaBio, investor - M.S.Q. Ventures is pleased to announce that its client, BioLineRx, has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. and an associated investor for the development of motixafortide across all indications in Asia. The license agreement provides for a $15M upfront payment and an equity investment of $14.6M, up to $50M in potential development and regulatory milestones, up to $200M in potential commercial milestones and tiered double-digit royalties on sales.

09:03 EDT Shuttle Pharmaceuticals licenses IP for prostate cancer biomarker program - Shuttle Pharmaceuticals has entered into an exclusive agreement to license certain intellectual property from Georgetown University to advance Shuttle Pharma's predictive biomarker program for prostate cancer. The intellectual property was originally developed through a collaboration of Shuttle Pharma scientists with investigators from Georgetown University. Shuttle Pharma's predictive marker strategy is to develop a predictive diagnostic test for prostate cancer patients who are considering elective radiation therapy which will allow them to assess their risk for treatment success or failure, while informing therapeutic decision making and follow-up management. Shuttle Pharma scientists have collaborated with investigators from Georgetown University to complete Phase I and Phase II NIH SBIR contracts to develop predictive biomarkers of radiation therapy outcomes and late effects. Shuttle Pharma will also seek to leverage eligibility to apply for project bridge funding via an NIH Phase IIb SBIR mechanism.

08:59 EDT Abbott, Stereotaxis report patients treated with integrated tech in the U.S. - Stereotaxis announced the first patients in the United States have been treated successfully utilizing Abbott's EnSite X EP System integrated with Stereotaxis' Robotic Magnetic Navigation System. The integration of Abbott's leading cardiac mapping system and Stereotaxis' advanced robotic technology, first announced at Heart Rhythm 2023, combines highly detailed real-time diagnostic information with the unprecedented precision and stability of robotics during therapy delivery. The first integrated procedures in the US were completed by physicians at Weill Cornell Medical Center, Mount Sinai Morningside, Banner University Medical Center Phoenix, and Overland Park Regional Medical Center.

08:50 EDT GRI Bio presents data on approach of NKT Cell Modulators at AFDD Summit - GRI Bio announced the presentation of data supporting its novel approach to inflammatory diseases at the 7th Annual Antifibrotic Drug Development, AFDD, Summit held October 24-26, 2023 in Boston, MA. As part of the AFDD Summit, Vipin Kumar, PhD, Chief Scientific Officer of GRI Bio gave an oral presentation titled, "Exploration of NKT Cell Activation as an Immune Biomarker for Progression of Fibrosis." "We continue to be encouraged by the data being generated by GRI-0621 and the translational work we are doing with our collaborators that demonstrate a significant increase in iNKT cell numbers in IPF patients and their correlation with biomarkers of fibrosis and disease," commented Dr. Kumar. "Looking ahead, we are making progress toward launching our Phase 2a biomarker study for GRI-0621 before year end." Key Highlights: GRI-0621 has demonstrated itself as a potent inhibitor of iNKT cell activity. iNKT cells have an activated phenotype in NASH & IPF patients. Enhanced iNKT activity correlates with progression of fibrosis in NASH patients and with macrophage accumulation and key proinflammatory genes in BAL from IPF patients. iNKT cells are activated and accumulate in liver and lung in experimental fibrosis models. iNKT promotes Type 1, Type 2 and Type 3 immune pathways involved in fibrosis. iNKT-deficient mice have reduced inflammatory damage and fibrosis. Daily oral administration of GRI-0621 in experimental animals: Inhibits pro-inflammatory cytokines and inflammation; Decreases accumulation of neutrophils and proinflammatory macrophages; Inhibits key fibrogenic cytokines including TGF-b and fibrosis.Phase 2 study with GRI-0621 in IPF patients to examine iNKT activity along with key biomarkers.

08:45 EDT Evoke Pharma, EVERSANA unveil cost savings real-world data of GIMOTI - Evoke Pharma announced a summary of real-world data on the positive impact of GIMOTI usage in reducing healthcare costs for patients suffering from diabetic gastroparesis versus patients taking oral metoclopramide. The full abstract entitled "Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs for Treating Diabetic Gastroparesis Patients," was selected and presented for a plenary session at the American College of Gastroenterology 2023 Annual Meeting in Vancouver, Canada. The data describes the results of a comparative study that highlights cost-related healthcare resource utilization data in DGP patients taking GIMOTI versus those on oral metoclopramide over a six-month period. HCRU is the description and quantification of patients' total usage of healthcare services such as emergency department visits, hospitalization or how often they visit a healthcare provider in the office. With these leading-edge HRCU data in hand, this study aimed to uncover whether reduced healthcare resource utilization would translate to overall health care savings and reductions in costs associated with inpatient hospitalization, emergency department, hospital outpatient, physician office, lab/home/telehealth, and pharmacy for DGP patients treated with NMCP vs. OMCP. Over the 6-month post index period, NMCP patients/payers spent approximately $15,000 less than OMCP patients/payers between medical facility and pharmacy visits; Total pharmacy costs in the NMCP cohort were numerically higher than pharmacy costs in the generic OMCP group but were not statistically significantly higher; More than half of OMCP treated subjects visited the inpatient and ED healthcare settings in the 6-month post treatment index than those treated with NMCP; NMCP patients spent only $115 in inpatient facilities versus $10,136 spent by OMCP patients within the 6-month post-index period; Lower real-world cost for NMCP versus OMCP patients were primarily driven by markedly reduced costs across key sites of care: inpatient hospitalizations, hospital outpatient and ED visits

08:42 EDT Coyote Logistics joins TriumphPay Payments Network - TriumphPay announced the addition of Coyote Logistics to its open payments network. The TriumphPay open payments network has rapidly expanded since its launch in January 2022, now with over 30 of the top 50 U.S. brokers as clients, creating a more secure hub for the presentment, audit and payment of invoices in the transportation industry.

08:41 EDT BAIYU Holdings and JD.com subsidiaries sign payment service agreement - BAIYU Holdings (BYU) subsidiary Shenzhen Tongdow signed a service agreement with a wholly-owned subsidiary of Beijing Jingdong Financial - JD Tech - to jointly launch a trading payment platform for commodity enterprises. JD Tech, an affiliate of JD.com (JD), is a specialized business arm committed to leveraging technology to serve various industries. It aspires to deliver end-to-end technical products and solutions to a diverse clientele including enterprises, financial institutions, and governments. This agreement provides technical support for enterprise payment settlements and supply chain financing for bulk customers of the company's subsidiaries. At present, the company is committed to the network layout of photovoltaic, energy storage power and fast charging stations and the operation service of new energy industry. In the future, the company plans to deepen its cooperation with JD Digits in areas like enterprise payment and settlement, supply chain finance, etc.

08:40 EDT Apollomics announces two new cohorts in global Phase 2 SPARTA study - Apollomics announced the addition of two new cohorts in its ongoing global multi-cohort Phase 2 SPARTA study, which is evaluating vebreltinib in patients with non-small cell lung cancer and other solid tumors with MET dysregulations, including exon14 skipping mutation, c-MET amplification and MET fusion. The first new cohort, labeled C-2, is evaluating the addition of vebreltinib to epidermal growth factor receptor tyrosine kinase inhibitor, such as osimertinib, for patients with EGFR-mutated NSCLC progressing on first line EGFR inhibitor therapy to address acquired resistance due to c-MET amplification. The second new cohort, labeled F, will evaluate vebreltinib monotherapy in histology-agnostic solid tumors with wild type MET gene that have high expression of c-MET and hepatocyte growth factor. "We are pleased to further expand the potential target indications in our Phase 2 SPARTA study by the addition of two new cohorts to include patients for whom there are no approved target therapy for addressing the tumor proliferation and/or treatment resistance resulting from dysregulations in the HGF/c-MET axis," said Peony Yu, M.D., Chief Medical Officer of Apollomics.

08:39 EDT Caterpillar says 'healthy demand across most end markets' - Says sales "generally in-line with expectations" in Q3. Says product availability and lead times have improved. Says backlog still elevated compared to historical levels. Says "very comfortable" with dealer inventory levels. Expects full year results to be "better than expected." Comments taken from Q3 earnings conference call.

08:39 EDT Biotricity releases Biotres Pro product - Biotricity announced their expansion of the current Biotres product platform. The new product, known as Biotres Pro, adds cellular backup for offline connectivity in addition to the existing unique feature set. The company said, "Biotres has been a game-changing product to the cardiac health market since its release. Biotres Pro continues this trend and establishes Biotricity's product portfolio as the most comprehensive remote cardiac monitoring product portfolio globally. Biotres is a unique innovative ECG cardiac monitoring device that provides 3 channels of continuous ECG data. The device offers physicians enhanced accuracy into heart health. The company recently filed a patent application to protect its cutting edge 3 channel technology, which is a significant step forward in compact devices. Biotricity has now taken it a step further with the new addition of Biotres Pro, another version of Biotres that combines cutting edge 3 channel technology with cellular backup for those with little connectivity, minimal access to a cellphone, or simply experience trouble connecting the device. The cellular capability of Biotres Pro ensures that the device will continue to offload data in instances of minimal connectivity. This is a groundbreaking solution as current compact devices only have 1 to 2 channels and are limited in or lack connectivity."

08:37 EDT Third Harmonic Bio announces CSO Ray's transition to SA, CFO Ho to depart - Third Harmonic Bio announced the transition of Adrian Ray, Ph.D., from Chief Scientific Officer, CSO, to Scientific Advisor, SA, effective November 1, 2023. In his new role, Dr. Ray will continue support the company's Investigational New Drug, IND, application for THB335, which is expected to be filed during the first half of 2024. Additionally, the company announced that Robert Ho, Chief Financial Officer, CFO, will depart the organization on November 10, 2023. The company has initiated executive searches for their successors.

08:35 EDT Maris-Tech receives $625,000 follow-on order for Opal platform - Maris-Tech announced a $625,000 repeat order for units of the Company's Opal platform from a leading Israeli defense company.The advanced Opal platform is based on Maris-Tech's flagship Jupiter AI platform, a high-end multiple stream video platform with AI acceleration that delivers real-time intelligence gathering and analytics. Maris-Tech has already delivered previously placed purchase order in the amount of $500,000 for the Opal platform. Maris-Tech expects to deliver the units pursuant to this purchase order during the years 2023 and 2024.

08:33 EDT Sabre selected by Virgin Australia as preferred NDC IT technology provider - Sabre has been selected by Virgin Australia to power its future New Distribution Capability - NDC - connection. Virgin Australia will use Sabre's NDC IT capabilities, together with its Global Distribution System, to both create and distribute innovative offers and rich, customised NDC content. Virgin Australia will deploy Sabre technology to power its future retailing efforts across both direct and indirect channels. The carrier recently chose two new solutions from Sabre's Retail Intelligence suite, together with renewing its multi-year Sabre distribution agreement that includes the future addition of NDC content.

08:31 EDT Greif announces it plans to acquire IPACKCHEM in cash transaction valued $538M - Greif announced that it has entered into exclusive negotiations to acquire IPACKCHEM Group SAS, a global leader in premium barrier and non-barrier jerrycans and small plastic containers, from an affiliate of SK Capital Partners, in a cash transaction valued at $538M. The planned transaction would be funded through available capacity in Greif's existing credit facilities and would be expected to close by the end of the second quarter of Greif's 2024 fiscal year, subject to prior completion of the information-consultation processes under French law and closing conditions, including regulatory clearances. "The IPACKCHEM portfolio is in perfect alignment with Greif's strategic growth aspirations in jerrycans and other small plastics," said Greif's President and Chief Executive Officer, Ole Rosgaard. "Its state-of-the-art facilities are located in many of the regions we already serve, leading to significant value creation opportunities. Further, IPACKCHEM allows us to enter into new and attractive geographies and end markets with a scaled position upon which we can further grow through organic investment. Greif is excited and will be eager to welcome the IPACKCHEM colleagues to our family and create lasting value together when the planned transaction is completed."

08:30 EDT Modular Medical updates test progress, submission timeline - Modular Medical provided an update on its ongoing pre-submission testing and timeline for submission of its MODD-1 insulin pump to the U.S. Food and Drug Administration. The Company has made substantial progress on completing many of the tests required for submission and now has results back from some of the longest lead time tests, including insulin stability and potency. Modular Medical believes the test results received from multiple third-party laboratory tests are sufficient for submission of the MODD1 to the FDA for clearance, subject to the completion of other ongoing tests and reports. Jeb Besser, CEO of Modular Medical, commented, "The Modular Medical team has continued to make rapid progress towards our 510(k) submission to the FDA, since the completion of our pilot manufacturing line in August. While there is still additional testing to be done, we are starting to gain better visibility on our submission timeline, and we currently expect to make our FDA submission around year end 2023. We remain excited about our opportunity to bring access to better insulin delivery to underserved segments of the market."

08:29 EDT Lightspeed releases new features to merchants - Lightspeed Commerce is announcing a roster of new product features recently released to merchants. "Merchants start businesses out of passion, not because they love spending hours on inventory, reconciliation, or schedules," said Ryan Tabone, Chief Product and Technology Officer of Lightspeed. "Our job as their technology partner is to empower them with the tools that simplify how they operate, so they can focus on their customers and scale their business. This latest round of new product features is the start of a string of functionality that gives them that ability, as well as an edge in their respective markets."

08:27 EDT Panbela Therapeutics announces validation of European Patent for SBP-101 - Panbela Therapeutic announced validation for the European patent 2019213664 titled "METHODS FOR PRODUCING-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL" in the United Kingdom, Italy, Germany, France, and Spain. This patent, developed in collaboration with Syngene International Ltd., an integrated research, development, and manufacturing services company, claims a novel process with a reduced number of synthetic steps from seventeen to six to produce SBP-101, a lead investigational product. The patent is valid until 2039. Jennifer Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela Therapeutics, commented, "We're excited to have this European patent now validated in individual countries." First issued in the United States in 2021 and now in several other territories, this patent covers a shorter synthesis of SBP-101, which provides many benefits including a scalable, efficient and cost-effective manufacturing process to enable future commercialization.

08:25 EDT First Quantum Minerals provides update on Panama - First Quantum Minerals notes the October 29 announcement by President Laurentino Cortizo of the Panamanian government's intention to hold a popular consultation on December 17 concerning Law 406. Law 406, recently enacted by the National Assembly of Panama, approved the Company's Panamanian subsidiary's, Minera Panama, revised contract for the Cobre Panama mine. First Quantum has contacted the government in order to understand the details in respect of the popular consultation. The Company also notes the comments by the Electoral Commission of Panama in respect of the legal and logistical considerations in respect of the popular consultation. The government has said that it plans to shortly introduce a bill to parliament in respect of the popular consultation process. Additionally, the Company also notes the unconstitutionality challenges that have been brought against Law 406 and that currently two of them have been admitted to be heard by the Supreme Court of Justice. First Quantum has always been an advocate of Panama and its people and is committed to the rule of law with the objective to achieve benefits the country, its citizens, the Company and its stakeholders. We are proud to be a significant contributor to the Panamanian economy and to create employment and empowerment opportunities for tens of thousands of Panamanians and sponsor a wide range of social, cultural and biodiversity programs across the country. We are fully committed to operating in an environmentally sensitive manner, by meeting all environmental compliance obligations and by supporting Panama's biodiversity through our reforestation, species conservation and protected areas plans. We remain committed to reforesting almost double the area that we mine. The protected areas and national parks that we support represent more than 30 times the footprint of our mine. As the largest private investment in the history of Panama, the Cobre Panama mine now contributes almost 5 percent of Panama's Gross Domestic Product, makes up 75 percent of the country's export of goods and has created at least 40,000 jobs, directly and indirectly, that we estimate support 100,000 or more Panamanians and their families. We believe in this project and its potential and welcome the opportunity to have constructive dialogue with the people of Panama about its future. We remain focused on the safety and well-being of our more than 8,000 employees who continue to operate the mine.

08:23 EDT Super League Enterprise marks one-year milestone of partnership with Nuverse - Super League announces one year of a fruitful partnership with Nuverse, the video game development and publishing subsidiary of Bytedance. Together, they have been creating monthly in-game and social media content for the hit mobile title MARVEL SNAP. "Our team loves MARVEL SNAP!" said Matt Edelman, President and Chief Commercial Officer for Super League. "We were already playing the beta version of the game when the opportunity to work with the Nuverse team appeared, so it's been easy to pour our passion into every piece of content we create. The Marvel brand and fanbase are the world's best, and we enjoy thriving under the pressure that such high expectations bring."

08:22 EDT Caterpillar sees FY23 restructuring expense about $700M - Sees FY23 CapEx about $1.5B; Estimated global tax rate of about 22.5%, excluding discrete items. Comments taken from investor presentation slides.

08:20 EDT Rigetti Computing appoints Iannotti as Chairman of the Board of Directors - Rigetti Computing (RGTI) announced that it has appointed Thomas Iannotti as Chairman of the Board of Directors, effective immediately. Iannotti succeeds Cathy McCarthy in the role of Chair, with Ms. McCarthy continuing to serve as a member of the Board of Directors. Iannotti currently serves as Chairman of the Board of Directors at Applied Materials (AMAT), a role which he has held since 2017.

08:18 EDT X4 announces FDA acceptance with priority review of U.S. NDA for mavorixafor - X4 Pharmaceuticals announced that the United States Food and Drug Administration, FDA, has accepted for filing the company's New Drug Application, NDA, for once-daily, oral mavorixafor to treat individuals aged 12 and older with WHIM syndrome, a rare, primary immunodeficiency. The FDA granted Priority Review of the mavorixafor NDA, establishing a goal of six months review from the date of acceptance and assigning a Prescription Drug User Fee Act, PDUFA, target action date of April 30, 2024. "The FDA's acceptance of our mavorixafor NDA with priority review represents yet another significant step forward towards a potential treatment for those with WHIM syndrome, a rare disease for which there are currently no approved therapies," said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. "We look forward to working closely with the FDA throughout the NDA review process with the goal of bringing mavorixafor to people with WHIM syndrome as quickly as possible."

08:18 EDT PaxMedica acquires certain suramin research assets from RLS - PaxMedical announced the successful acquisition of certain suramin research assets from Rediscovery Life Sciences, RLS. These assets were previously dedicated to the study of suramin's potential efficacy in treating acute kidney injury resulting from chronic kidney disease. The newly acquired data from RLS will play a crucial role in bolstering PaxMedica's ongoing efforts to support the submission for the approval of PAX-101, specifically for the treatment of African Sleeping Sickness caused by the Trypanosoma brucei rhodesiense parasite. This strategic move follows PaxMedica's recent Type B meeting with the FDA. In a recent statement, Howard Weisman, Chairman and CEO of PaxMedica, emphasized the significance of this acquisition, stating, "Acquiring the research assets from Rediscovery Life Sciences marks a significant leap forward in our journey to expedite the NDA submission process for PAX-101. This valuable addition of data will significantly contribute to our mission of delivering effective and life-saving treatments for Human African Sleeping Sickness."

08:16 EDT aTyr Pharma announces dosing of first patient in Phase 2 EFZO-CONNECT study - aTyr Pharma announced that it has dosed the first patient in its Phase 2 EFZO-CONNECT study. The proof-of-concept study will evaluate the efficacy, safety and tolerability of the Company's lead therapeutic candidate, efzofitimod, compared to placebo in patients with systemic sclerosis-related interstitial lung disease, ILD. "We are very pleased to begin patient dosing in EFZO-CONNECT(TM), which is our second clinical study for efzofitimod in ILD," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Efzofitimod has been shown preclinically to reduce lung and skin fibrosis in models of SSc, and NRP2, efzofitimod's binding partner, is expressed in the skin of SSc patients. We believe there is compelling rationale that efzofitimod has the potential to target the underlying disease pathology central to this form of ILD and positively impact lung function and improve outcomes in these patients."

08:16 EDT NexPoint Residential raises quarterly dividend 10.1% to 46.24c per share - Payable on December 29 to stockholders of record on December 15. This represents a 10.1% increase over the previous quarter's distribution and an increase of 124.5% since inception in 2015.

08:15 EDT ZimVie announces first U.S. surgery with 4.5mm Mobi-C Cervical Disc - ZimVie announced that the first patient in the United States has received the newly approved 4.5mm Mobi-C Cervical Disc. On October 30, 2023, Gregory D. Lopez, M.D., orthopaedic spine surgeon with Midwest Orthopaedics at Rush in Chicago, Illinois, implanted the first 4.5mm Mobi-C in the United States. "The 59-year-old patient presented with a significantly collapsed C5-6 disc, and the new lower profile Mobi-C implant allowed me to avoid over-distracting the facet joints. The 4.5mm height Mobi-C makes it possible for me to offer pain relief and motion preservation to more of my patients with cervical disc degeneration." "It is an honor to celebrate the first U.S. implantation of the 4.5mm Mobi-C Cervical Disc. ZimVie is dedicated to bringing the right products to the market, and it really hits home to know that patients are benefiting from our efforts," said Rebecca Whitney, Global President of ZimVie Spine. "We are excited about the recent wins for our market-leading Mobi-C portfolio, including the August FDA approval for the 4.5mm range of implants and the September approval of the Mobi-C Hybrid Investigational Device Exemption application, allowing ZimVie to enroll patients in the first ever cervical arthroplasty-fusion study in the United States."

08:14 EDT 23andMe launches Health Action Plan to provide personalized recommendations - 23andMe launched Health Action Plan, a new digital tool for 23andMe+ members that draws on results from genetic reports, health history survey data, as well as blood and biomarker data to provide a uniquely tailored set of health recommendations out of hundreds of options. "Health Action Plan is a powerful tool for customers, combining genetic and non-genetic data, along with lab testing to tailor health recommendations," said Robin Smith, Ph.D., Director of Product Management at 23andMe. "This feature provides customers with a prioritized to-do list of recommendations based on their DNA that's updated as new reports are released or additional scientific discoveries are made."

08:13 EDT INmune Bio updates on patent covering INB16, INKmune therapeutic composition - INmune Bio announced an update regarding the company's patent covering its proprietary cell line, "INB16", as well as the therapeutic composition comprising replication-incompetent INB16 cells known as "INKmune" and methods of treating cancer by administering INKmune, with a goal of achieving in vivo priming of natural killer cells to enhance the ability of a patient's own NK-cells to effect cancer surveillance, recognition, and killing. In the written opinion for the international patent application titled, "HUMAN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CELL LINE & APPLICATIONS FOR TREATING CANCER," an examiner from the International Search Authority at the United States Patent & Trademark Office, authorized by the World Intellectual Property Organization under the Patent Cooperation Treaty, issued a favorable patentability opinion with respect to novelty, inventive step and industrial applicability of all claims and concluding that the application contains patentable subject matter. The application discloses and claims the novel INB16 cell line on deposit with the American Type Culture Collection, as well as compositions comprising replication incompetent INB16 cells and methods of treating cancer in patients by administering INKmune.

08:12 EDT Telus, FLO agree expand connectivity on FLO EV across North America - TELUS and FLO announced an agreement to bring TELUS' world-leading connection to FLO chargers. With most light-duty vehicles sold in Canada expected to be required to be zero emissions by 2035, TELUS will support FLO's development of critical infrastructure helping to drive the adoption of electric vehicles and support the reduction of greenhouse gas emissions. FLO will leverage TELUS' dedicated IoT network solutions and connectivity platforms in FLO public and commercial Level 2 and Direct Current Fast Chargers across North America. "This agreement underpins TELUS' commitment to lead in sustainability, finding ways to use our world-leading connectivity and technology to drive environmental change, build intelligent cities and create a more sustainable future. This exciting step demonstrates how innovation and quick evolution in the EV space is providing a better experience for customers," said Navin Arora, Executive Vice-president, TELUS and President, TELUS Business Solutions and TELUS Agriculture & Consumer Goods.

08:10 EDT BigBear.ai expands partnership with Thomas Jefferson University Hospital - BigBear.ai announced that Thomas Jefferson University Hospital is expanding its use of BigBear.ai's AI platform to make day-to-day operations improvements to centralized resource and bed management, nurse staffing, and its transfer center. "BigBear.ai is thrilled to expand its work with Thomas Jefferson University Hospital," said Greg Goldwater, Chief Growth Officer at BigBear.ai. "Because BigBear's Predictive AI platform can effectively predict the future through event simulation, it's a game-changer for hospital systems looking to roll out strategic growth plans. We look forward to our next phase of collaboration that will ultimately drive better patient care and outcomes."

08:09 EDT PTC's Codebeamer ALM solution adopted by Volkswagen Group - PTC has established a strategic supplier relationship with Volkswagen Group, focused on the adoption of PTC's Codebeamer application lifecycle management - ALM - solution to support the software development for the next generation of electric vehicles from the Volkswagen Group and its brands. Codebeamer is expected to enable greater efficiencies in Volkswagen Group's engineering practices for software requirements management, test management, and release management as part of new electric vehicle development. PTC and Volkswagen Group expect to scale the use of Codebeamer across multiple Volkswagen Group engineering teams to support the software development process.

08:08 EDT LogicMark appoints Carine Schneider, Tom Wilkinson to board - LogicMark announced that Carine Schneider, FGE, and Tom Wilkinson will join as the newest members of its Board of Directors. Schneider is a co-founder of Compass Equity Strategic Advisors and possesses extensive experience in the private market and global compensation industry. Wilkinson is a professional advisor and consultant through his businesses, Wilkinson & Company and re/Manifest, which he founded to provide turn around, M&A and business growth advisory services.

08:08 EDT Quantum Computing achieves first sale of Reservoir Computer - Quantum Computing announced a milestone in its quest to bring cutting-edge quantum solutions to the market. The company has secured multiple hardware sales of its state-of-the-art Reservoir Computer and Quantum Random Number Generator to Assured Cyber Protection Ltd and AI firm millionways, kicking off the commercial delivery of its computing technologies. The QCi Reservoir Computer, a first-to-market portable reservoir computing device with technology inspired by the power of quantum mechanics, can perform complex computational tasks with unprecedented speed and efficiency to facilitate data analysis, machine learning and artificial intelligence. Its minimal size, weight, power, and cost factors make it particularly suitable for use as an edge computing tool. QCi's Reservoir Computer uses the company's proprietary capabilities to create a small footprint hardware device that requires 80% to 95% less power consumption than traditional computers. The QCi Reservoir Computer series leverages the Company's unique competencies and expertise in both analog and digital design, resulting in an innovative piece of technology that interfaces seamlessly with a host machine through an Ethernet connection, enabling smooth communications and problem-free submission. The Reservoir Computer, available now, is QCi's first major step on its path to building a hardware-based, Quantum Reservoir Computer to be released in 2024.

08:07 EDT Kintara Therapeutics suspends development of VAL-083 after topline results - Kintara Therapeutics announced that preliminary topline results from the Glioblastoma Adaptive Global Innovative Learning Environment study showed that VAL-083 did not perform better than the current standards of care in glioblastoma. These topline results included preliminary safety data for VAL-083 that was similar to that of the current standards of care used to treat glioblastoma. With this study outcome, Kintara is suspending the development of VAL-083 and turning its focus to its second program, REM-001. In addition to focusing on its REM-001 program, Kintara will evaluate a range of strategic options aimed at potentially maximizing shareholder value. All development activities and related costs for VAL-083 will be suspended while the company awaits the full dataset from the GBM AGILE Study which is expected at the end of Q1/beginning of Q2 of 2024. At such time Kintara will analyze the full results as it seeks to maximize the value of the VAL-083 asset. Kintara expects to enroll the first subject in a 15-patient CMBC study around the end of calendar year 2023. The company was recently awarded a $2M grant from the National Institutes of Health which is expected to cover the majority of the cost to run the CMBC study. In November 2022, the FDA granted Fast Track Designation to Kintara's REM-001 Therapy for the treatment of patients with CMBC.

08:05 EDT Acadia Healthcare to pay $400M to settle Desert Hills litigation - In a regulatory filing, Acadia Healthcare announced that it and its subsidiary Youth and Family Centered Services of New Mexico entered into settlement agreements in connection with Acadia and Desert Hills' previously disclosed civil litigation in New Mexico State District Court. The Settlement Agreements fully resolve each of the Cases and include no admission or finding of liability by Acadia or Desert Hills, Acadia said. Under the terms of the Settlement Agreements, which are subject to approval by the District Court, the company will pay an aggregate amount of $400M in exchange for the release and discharge of all claims arising from, relating to, concerning or with respect to all harm, injuries or damages asserted or that may be asserted in the future. Because the settlement funds will be excluded from adjusted EBITDA, the settlement has no impact on the company's previously announced financial guidance. The company also affirmed that it maintains a strong financial position with sufficient capital to make strategic investments in its business.

08:04 EDT Accenture to acquire U.K. technology consultancy 6point6, no terms - Accenture has signed an agreement to acquire 6point6, a U.K. technology consultancy, specializing in cloud, data, and cybersecurity. Spanning the commercial and public sectors, the acquisition will enhance Accenture's strategy and architecture capabilities, with a particular emphasis on central government, defense and security, and financial services... Ashish Goel, managing director for Accenture Health and Public Service in the U.K. and Ireland, added, "Defense, public safety, and national security are becoming increasingly prioritized by the U.K. government. In just over a decade, 6point6 has leveraged its experienced leadership team and key accreditations to generate strong relationships across these sectors which, alongside Accenture's capabilities, adds to our ability to deliver truly differentiated services to clients." Completion of the acquisition is subject to customary closing conditions, including receipt of regulatory clearance. Terms of the transaction were not disclosed.

08:03 EDT Mersana Therapeutics says FDA lifts clinical hold on Phase 1 trial of XMT-2056 - Mersana Therapeutics announced that the U.S. Food and Drug Administration has lifted the clinical hold on the company's Phase 1 clinical trial of XMT-2056. XMT-2056 is a systemically administered Immunosynthen STING-agonist ADC that is designed to target a novel human epidermal growth factor receptor 2 epitope and locally activate STING signaling in both tumor-resident immune cells and in tumor cells, providing the potential to treat patients with HER2-high or -low tumors as monotherapy and in combination with standard-of-care agents. The multicenter Phase 1 open-label trial is investigating XMT-2056 in previously treated patients with advanced/recurrent solid tumors expressing HER2, including breast, gastric, colorectal and non-small-cell lung cancers. The dose escalation and dose expansion portions of the trial will evaluate and characterize the relationship of safety, tolerability and exposure of XMT-2056 and this candidate's preliminary anti-tumor activity, as measured by overall response rate, duration of response and disease control rate.

07:58 EDT Cybin reports CYB003 demonstrated reduction in symptoms of depression - Cybin announced Phase 2 interim results for CYB003, its proprietary deuterated psilocybin analog, demonstrating a statistically significant reduction in symptoms of depression three weeks following a single 12mg dose compared to placebo. At the three-week primary efficacy endpoint, the reduction in major depressive disorder, or MDD, symptoms, defined as change from baseline in MADRS total score, was superior in participants assigned to CYB003 compared to the participants who received placebo by 14.08 points. A p-value indicates statistical significance. Generally, values less than 0.05 are considered statistically significant and values less than0.001 are considered highly statistically significant. The Phase 2 clinical trial is evaluating efficacy using the MADRS scale, with a primary efficacy endpoint of reduction in depression symptoms at week 3 after a single administration. To date, dosing has been completed in all dose cohorts up to 16mg, with a favorable safety and tolerability profile and no treatment-related serious adverse events observed. Interim results from the 12mg dose cohort have demonstrated a statistically significant and clinically meaningful reduction in symptoms of depression with a single dose at three weeks after treatment. The MADRS is a 10-item, clinician-administered scale designed to measure overall severity of depressive symptoms in subjects with MDD. It is widely used in clinical trials and accepted by regulatory authorities worldwide as a measure of symptoms of depression. The MADRS includes items ranging from sadness of mood, reduction in sleep and appetite, to difficulties in concentration, anhedonia, and negative and suicidal thoughts that are scored from 0 to 6 giving a total score ranging from 0 to 60. Typical score ranges for severity are: 0-6 normal; 7-19 mild; 20-34 moderate; and greater than34 severe depression. In the CYB003 study, mean baseline total scores on the MADRS were 32.6 and 33.3 in the active and placebo groups, respectively. Rapid and statistically significant improvements in depression symptoms observed after single doses of CYB003: Improvements in depression symptoms evident on the day after dosing, reaching a peak 10 days after dosing, and maintained thereafter. Robust and statistically significant reduction in depression symptoms compared to placebo at 3 weeks, with a -14.08 difference in change from baseline in MADRS for CYB003 vs. placebo. Robust response rates at three weeks after single dose: 53.3% response rate for CYB003 vs. 0% for placebo, 20.0% remission rate for CYB003 vs. 0% for placebo. CYB003 was well tolerated with no drug-related Serious Adverse Events. All Adverse Events were mild or moderate in intensity and resolved spontaneously without intervention. Full topline safety and efficacy data from the CYB003 MDD study is expected by the end Q4 2023, with 12-week durability data anticipated in Q1 2024. Cybin plans to submit this topline data to the FDA and request an end of Phase 2 meeting to be held in Q1 2024. Recruiting for a CYB003 Phase 3 study is anticipated to begin by the end of Q1 2024. The company also expects to share topline Phase 1 data for CYB004 and SPL028, its proprietary novel deuterated N,N-dimethyltryptamine compounds, before the end of 2023, supporting the initiation of a Phase 2 study in participants with generalized anxiety disorder in Q1 2024.

07:45 EDT X-energy, Ares Acquisition mutually agree to terminate business combination - X-Energy Reactor Company, X-energy, a leading developer of advanced small modular nuclear reactors and fuel technology for clean energy generation, and Ares Acquisition Corporation (AAC) a publicly-traded special purpose acquisition company, announced that they have mutually agreed to terminate their previously announced business combination agreement , effective immediately. As a result, the extraordinary general meeting of AAC shareholders scheduled for October 31 to approve the proposed transaction will be convened and then adjourned indefinitely. Additionally, the extraordinary general meeting of AAC shareholders scheduled for November 2 to vote on a proposal to extend the date by which AAC must consummate a business combination will be convened and then adjourned indefinitely...An investment vehicle affiliated with Ares Management Corporation (ARES) has agreed to make a private investment into X-energy in order to support X-energy's continued growth as a private company. Neither party will be required to pay the other a termination fee as a result of the mutual decision to terminate the business combination agreement. Pursuant to the terms of the termination agreement between AAC and X-energy, X-energy assumed from AAC and agreed to pay, perform and discharge the liabilities of AAC with respect to the payment in cash of certain fees, costs and expenses of AAC and its affiliates.

07:43 EDT ARway.ai enters AR wayfinding collaboration with iFii - ARway.ai announced its collaboration with the prestigious Institut fur Innovations- und Informationsmanagement to create an innovative AR navigation system on the iFii campus in Germany. This is a paid-partner deal, valued at 5 figures annually depending on usage. The deal also represents a significant growth opportunity, as iFii will refer ARway to other institutions and businesses in the EU by showcasing this project.

07:41 EDT Red White & Bloom says court grants approval of amended stalking horse agreement - Red White & Bloom Brands is providing an update on matters relating to Aleafia Health and other corporate matters. RWB is pleased to announce that in connection with the proceedings of Aleafia Health and certain of its subsidiaries under the Companies' Creditors Arrangement Act, the Ontario Superior Court of Justice has granted an approval and reverse vesting order in respect of the previously announced sale transactions. The Approval and Vesting Order is the sole authorization required by the Aleafia Group to implement the transactions provided for under the previously announced stalking horse asset purchase and share subscription agreement, as amended and restated on October 24, 2023 among RWB, Aleafia Health and certain of Aleafia Health's subsidiaries. The Approval and Vesting Order approves the implementation of the transactions contemplated by the Amended Stalking Horse Agreement, whereby a wholly-owned subsidiary of RWB would subscribe for shares of the Aleafia Purchased Entities and acquire specific intellectual property owned, licensed or leased by Aleafia Health. Certain excluded assets and liabilities of the Aleafia Purchased Entities would be transferred to one or more corporations that would not be included among the Aleafia Purchased Entities at closing. RWB's subsidiary would be the sole shareholder of the Aleafia Purchased Entities following closing. The Court also granted an ancillary relief order approving, among other things, amendments to the debtor-in-possession term sheet to increase the DIP financing available to the Aleafia Group from $6.6 million to $8 million; and an extension to the current stay period in the Aleafia CCAA Proceedings to November 30, 2023, in order to, among other things, permit the parties to complete the transactions contemplated under the Amended Stalking Horse Agreement. The consummation of the transactions contemplated under the Amended Stalking Horse Agreement is subject to satisfaction or waiver of certain conditions set forth in the Amended Stalking Horse Agreement, including, among other things, receipt of all required regulatory approvals and the Aleafia Purchased Entities' Health Canada and cannabis excise licences being in good standing and continuing in good standing and not suspended or terminated following the closing date. The parties anticipate closing the transactions contemplated under the Amended Stalking Horse Agreement following satisfaction of the remaining conditions to closing, and in any event no later than November 22, 2023. In accordance with the policies of the Canadian Securities Exchange, the Company announces that its board of directors has approved the issuance of 700,000 common shares on October 30, 2023, at a deemed price of $0.06 per share, as final consideration for an asset purchase completed by a wholly-owned subsidiary of the Company.

07:39 EDT Kite and Epic Bio announce collaboration to develop new therapies for cancer - Kite, a Gilead company and Epicrispr Biotechnologies or Epic Bio announced the companies have entered into a research collaboration and license agreement using Epic Bio's proprietary gene regulation platform to develop next-generation cancer cell therapies. The agreement will allow Kite to leverage the licensed technology to modulate certain genes to potentially enhance CAR T-cell functionality. "Cell-based cancer immunotherapies have reshaped modern cancer care, but we have still only scratched the surface of their potential benefit for patients."We are proud to partner with Kite to extend the potential application of Epic Bio's platform for cancer treatment..."Under the terms of the agreement, Epic Bio will develop constructs for Kite-selected targets for use in CAR T-cell therapies directed to blood cancers. Kite will make an upfront payment to Epic Bio and Epic Bio will be eligible to receive performance-based development, regulatory and sales milestone payments. Epic Bio is also eligible to receive tiered royalties on any approved products that result from the collaboration. The transaction with Epic Bio is expected to have a de minimis financial impact on Gilead's 2023 GAAP and non-GAAP EPS.

07:37 EDT Xoma earns $5M milestone upon FDA acceptance of Day One's tovorafenib NDA - XOMA (XOMA) announced it has earned a $5 million milestone related to the U.S. Food and Drug Administration's, FDA, acceptance of Day One Biopharmaceuticals' (DAWN) New Drug Application, NDA, for tovorafenib as a monotherapy for relapsed or progressive pediatric low-grade glioma. The FDA has granted tovorafenib Priority Review and established a Prescription Drug User Fee Act, PDUFA, date of April 30, 2024. "Tovorafenib has the potential to address a key unmet need in children whose low-grade gliomas with BRAF alterations have relapsed or progressed," stated Owen Hughes, Executive Chairman of XOMA. "A novel, targeted, orally available option has the opportunity to set a new standard-of-care in this patient population."

07:35 EDT Freeport-McMoRan to convert fleet of Caterpillar trucks to autonomous haulage - Caterpillar (CAT) and Freeport-McMoRan (FCX) are collaborating to convert the mining company's fleet of 33 Cat 793 haul trucks at its Bagdad mine in Arizona to an autonomous haulage system using Cat MineStar Command for hauling. Caterpillar and Freeport-McMoRan are collaborating to convert the mining company's fleet of Cat 793 haul trucks to an autonomous haulage system. Located approximately 100 mi northwest of Phoenix, Ariz., the Bagdad mine is a porphyry copper deposit containing both sulfide and oxide mineralization.

07:33 EDT Kiniksa sees 2023 ARCALYST net product revenue $220M-$230M

07:24 EDT Amgen reports Q3 total product sales up 5% y/y - Total product sales increased 5% for the third quarter of 2023 versus the third quarter of 2022. Unit volumes grew 11%, partially offset by 3% lower net selling price and 3% unfavorable changes to estimated sales deductions.

07:22 EDT Sterling Infrastructure reports Q3 transportation contract awards of over $470M - Sterling Infrastructure announced Q3 2023 Transportation Solutions awards totaling over $470M.

07:20 EDT OKYO Pharma announces $5.84M cash raise - OKYO Pharma announced a $5.84M issuance of shares via: a Company managed registered direct offering of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary share conducted without an underwriter or placement agent; and the extinguishment of payables of $4.20M by the issuance of 2,766,667 shares at the offering price of $1.50 per share. The reduction of payables is considered by the Company to be a major endorsement by its creditors of its current strategy and constitutes a material reduction of OKYO's payables. The gross cash proceeds to OKYO from the registered direct offering, before deducting offering expenses payable by OKYO, are expected to be $1.64M, together with a reduction of $4.20M of payables. The offering is expected to close on or about November 1 2023, subject to the satisfaction of customary closing conditions.OKYO intends to use the net proceeds from the offering primarily for clinical development of the Company's product candidates, general corporate purposes and working capital.

07:19 EDT Cleveland-Cliffs increases current base prices for steel products - Cleveland-Cliffs announced that it is increasing current spot market base prices for all carbon hot rolled, cold rolled and coated steel products, effective immediately with all new orders. Cliffs' minimum base price for hot rolled steel is now $900 per net ton.

07:18 EDT Lithium Ionic enters grid power connection contract with Cemig - Lithium Ionic reports that its 100%-owned Brazilian subsidiary, MGLIT Empreendimentos, has entered into an agreement with Cemig Distribuicao to facilitate the construction and electrification of essential power infrastructure between Cemig's existing power grid and the future Bandeira lithium operation, located approximately 3 kilometers away. The agreement aligns with the Company's goal of fast-tracking Bandeira towards production and solidifies its position as a near-term lithium producer in the region by securing low-cost, renewable hydroelectric power to meet the long-term requirements of the project. Cemig is the largest electricity distributor in Brazil, serving, through its network extensions, approximately 96% of the State of Minas Gerais. Lithium Ionic has commissioned an independent NI 43-101 compliant Feasibility Study for Bandeira, which is expected to be completed in early 2024. The FS follows the completion of a Preliminary Economic Assessment earlier this month, which supported a long-life and low-cost spodumene concentrate mining project with a post-tax Net Present Value 8% of US$1.6 billion and an Internal Rate of Return of 121% Details related to the Cemig Agreement include: The electrical transmission infrastructure will include 3 kilometres of new transmission lines, as well as a new substation adjacent to the future Bandeira mine. MGLIT will directly undertake the construction of the electric connection systems, including negotiations with contractors and suppliers, as well as the purchase of materials and services, in accordance with Cemig's pre-approved list. MGLIT and Cemig will jointly manage environmental licensing and land management. The total project cost is expected to be approximately BRL$17million. Following the completion of the project, the Company is eligible for reimbursement of up to BRL$2.98 million subject to certain requirements. The construction of the new electrical infrastructure is scheduled to be completed by Q4 2025, with electrification scheduled for the same period. Following the construction and a technical inspection by Cemig, the transmission lines and substation will be transferred to Cemig. The operation and maintenance of electrical infrastructure downstream of the new substation will be MGLIT's responsibility.

07:18 EDT Jeffs' Brands announces 1-for-7 reverse share split - Jeffs' Brands announced that it will conduct a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-7. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on November 3, 2023, under the Company's existing trading symbol "JFBR". The trading symbol "JFBRW" and CUSIP number for the Company's public warrants will remain unchanged following the reverse share split.

07:17 EDT USA Compression lowers 2023 net income view to $73M-$83M from $75M-$95M - Sees 2023 adjusted EBITDA $500.0M-$510.0M.

07:15 EDT Avalo Therapeutics completes divestiture of AVTX-800 series - Avalo Therapeutics announced it has completed the divestiture of its rights, title and interest in, assets relating to AVTX-801, AVTX-802 and AVTX-803 to AUG Therapeutics. The Company previously announced it entered into a purchase agreement with AUG to divest the 800 Series on September 12, 2023. AUG paid an upfront payment of $150,000, as well as, for each compound, is obligated to make a contingent milestone payment of $15,000,000 if the first Food and Drug Administration approval is for an indication other than a Rare Pediatric Disease, or up to 20% of certain payments, if any, granted to AUG upon any sale of any priority review voucher granted to AUG by the FDA, net of any selling costs. Additionally, AUG assumed $150,000 of certain liabilities incurred prior to the date of the Purchase Agreement and assumed all costs relating to the 800 Series from the date of the Purchase Agreement. "We are excited to announce that we have closed the transaction with AUG to divest our 800 Series programs for the treatment of congenital disorders of glycosylation. In AUG's hands, these programs could advance to provide reliable treatments for patients in need," stated Dr. Garry Neil, MD, Chief Executive Officer, and Chairman of the Board at Avalo Therapeutics. "Our pipeline is now fully focused on our promising immunology assets, reaffirming Avalo's unwavering commitment to execute its strategy of addressing unmet medical needs to patients suffering from immunological diseases, which we believe will derive the greatest value and potential for our shareholders. This transaction has an immediate positive impact on our cash flow and focuses the team fully on our core immunology assets, while also maintaining substantial upside potential for Avalo upon program success."

07:14 EDT Benson Hill expands liquidity improvement plan, including planned divestitures - Benson Hill announced plans to improve its financial position and accelerate its transition to an asset-light business model with a focused expansion into broadacre animal feed markets, complementing its accomplishments in human food ingredients. The near-term opportunity in animal nutrition is consistent with Benson Hill's strategy to expand and diversify its proprietary product portfolio, improve nutrition security, and foster collaboration with industry partners within the food value chain...Management is expanding the scope of its Liquidity Improvement Plan to maximize capital efficiency and provide a runway to execute the Company's strategy...The Company has taken actions to realize a $33M run rate operating expense reduction in 2024, with expectations for future reductions in operating expense savings and capital expenditures. Negotiations are underway to divest the Company's processing facilities. This includes a signed agreement to sell the soy crush facility in Seymour, Ind., for approximately $36 M of total gross proceeds, subject to working capital and other adjustments. ..the Company continues to evaluate multiple strategic alternatives through discussions with interested parties about executing its strategy under public and private operating models.

07:14 EDT Crispr Therapeutics announces NASDAQ halted trading of stock ahead of meeting - CRISPR Therapeutics announced that NASDAQ has halted trading of the Company's common stock. The U.S. Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee is meeting today to review the Biologics License Application for exagamglogene autotemcel) for the treatment of sickle cell disease in people ages 12 and older with recurrent vaso-occlusive crises. The Prescription Drug User Fee Act date for completion of the review of the BLA for exa-cel for SCD is December 8, 2023.

07:13 EDT Galera Therapeutics to discontinue both GRECO trials - "We are disappointed that the FDA did not find the data from our Phase 2b GT-201 and Phase 3 ROMAN trials sufficient for the approval of the NDA for avasopasem," said Mel Sorensen, M.D., Galera's President and CEO. "After discussing the data with the FDA, it is clear that their position is another Phase 3 trial is required." To optimize the Company's resources, it conducted a futility analysis of the GRECO-2 trial to assess the likelihood of a successful outcome. The analysis indicated that the trial was unlikely to succeed as designed. GRECO-2 is a randomized, double-blind, placebo-controlled Phase 2b trial evaluating rucosopasem or placebo in combination with SBRT in patients with LAPC. Overall survival is the trial's primary endpoint. The trial was designed to enroll 220 patients with final analysis at 120 events The trial has enrolled 177 patients to date, and the futility analysis was conducted based on 35 deaths with a data cutoff of October 9, 2023. Dr. Sorensen continued, "In light of our current resources and the results of the futility analysis, we have made the difficult decision to discontinue both GRECO trials. We will analyze the data collected to date to determine next steps for the asset, and we thank the patients and providers who participated in both trials."

07:12 EDT Galera Therapeutics says FDA confirms need for new trial for avasopasem for SOM - Galera Therapeutics has received official meeting minutes from the Type A meeting with the United States Food and Drug Administration held September 28, 2023 in which the FDA reiterated the need for an additional Phase 3 trial of avasopasem manganese for radiotherapy-induced SOM. The Company also decided to halt the Phase 2b GRECO-2 trial of rucosopasem manganese in patients with locally advanced pancreatic cancer and the Phase 1/2 GRECO-1 trial of rucosopasem in patients with non-small cell lung cancer, following a futility analysis of the GRECO-2 trial. The Company believes this decision will enable the Company to conserve cash while it continues to assess potential strategic alternatives with the goal of maximizing shareholder value. In the Type A Meeting minutes, the FDA reiterated that results from an additional Phase 3 trial will be required to support resubmission of the Company's New Drug Application for avasopasem in radiotherapy-induced SOM.

07:11 EDT Ametek acquires Amplifier Research, terms undisclosed - Ametek announced the acquisition of Amplifier Research Corp., a manufacturer of radio frequency and microwave amplifiers and electromagnetic compatibility, or EMC, testing equipment. Amplifier Research is a provider of amplifiers and EMC testing equipment for the defense, medical, communications and automotive markets. The company has a diverse product portfolio including RF and microwave instrumentation amplifiers, hybrid power amplifier modules, antennas, and control software used to provide high-end, EMC solutions. Amplifier Research is headquartered in Souderton, Pennsylvania and has annual sales of approximately $60M.

07:10 EDT Neurocrine sees 2023 Ingrezza net sales $1.82B-$1.84B

07:08 EDT GSK, Arrowhead announce deal with Janssen for rights to JNJ-3989 - GSK plc (GSK) and Arrowhead Pharmaceuticals (ARWR) announced that they have reached an agreement with Janssen Pharmaceuticals, a Johnson & Johnson (JNJ) company, to transfer exclusive worldwide rights to further develop and commercialise JNJ-3989 to GSK. JNJ-3989, formerly ARO-HBV, was initially in-licensed by Janssen from Arrowhead in 2018. JNJ-3989 is an investigational hepatitis B virus-targeted small interfering ribonucleic acid, or siRNA, therapeutic that GSK intends to evaluate in a sequential regimen with bepirovirsen, GSK's investigational antisense oligonucleotide, for the treatment of adult non-cirrhotic patients with chronic hepatitis B on nucleos(t)ide analogue therapy. Upon closing of the transaction, GSK will assume rights and obligations of the existing license agreement between Janssen and Arrowhead, including all remaining financial obligations owed to Arrowhead for JNJ-3989 under the original agreement. GSK will be responsible for upfront and potential milestone-based payments to both Janssen and Arrowhead totalling approximately $1B. Janssen will continue to be responsible for the ongoing clinical trials of JNJ-3989 at its expense and GSK will be solely responsible for all future development and commercialization activities. Additionally, Arrowhead will receive tiered royalties on net sales pursuant to the original agreement. This transaction is subject to customary conditions, including applicable regulatory agency clearances under the Hart-Scott-Rodino Act in the U.S. Tony Wood, Chief Scientific Officer, GSK, said: "We are excited to build on promising results already demonstrated with bepirovirsen to investigate a novel sequential regimen with JNJ-3989. We believe this approach could redefine the treatment paradigm for chronic hepatitis B by helping even more patients achieve functional cure."

07:03 EDT Sirius XM plans November 8 Next Generation event

07:00 EDT MPLX increases quarterly dividend 10% to 85c per unit - "Our business continues to grow and generate strong cash flow," said Michael J. Hennigan, MPLX chairman, president and chief executive officer. "We announced a 10% increase to our distribution, and through the first nine months of the year we have grown distributable cash flow over 6% compared to the same period in 2022."

06:52 EDT Zynex initiates review of strategic alternatives - Zynex announced its board of directors has initiated a process to evaluate potential strategic alternatives to maximize shareholder value. As part of the process, the board will evaluate, together with its advisors, a range of potential strategic alternatives which may include, any take private offers, a sale, merger or other business combination, a divestiture, a recapitalization, or other strategic transactions, or continuing to operate as a public, independent company.

06:45 EDT Samsung expects consumer sentiment to improve somewhat in VD in 2024 - The company said, "VD: Various external risks are likely to persist in the market, but we expect consumer sentiment to improve somewhat and ease the decline in market demand compared to 2023. We will continue to innovate products centering on premium/lifestyle screens and lead the ultra-high- definition/ultra-large TV market, targeting demand linked to sporting events. Moreover, we will continue to actively promote not only our basic competitiveness, such as picture and sound quality, but also product experiences related to the environment, security, and content, which have recently emerged as important consumer values. DA Digital Appliances will strengthen its leadership in premium segments via simultaneous global launches of home appliances featuring AI amid the advancement of interconnection experiences between SmartThings-based digital appliances and devices. We will also continue to improve the profit and loss structure by expanding sales of high-margin products, such as system air conditioners, and realizing operational efficiencies."

06:42 EDT Samsung says MX aims to grow annual flagship shipments by double digits - For 2024, the company said, "MX: We expect the smartphone market to grow, centering on the flagship segment, as consumer sentiment stabilizes in anticipation of a soft landing of the global economy. Tablet demand is forecast to rise, focusing on premium devices, andTWS demand should grow slightly amid a growing mass market. MX aims to grow annual flagship shipments by double digits and achieve smartphone revenue growth exceeding the market growth. For tablets, it will focus on strengthening the premium product line-up to meet demand for large screens. For wearables, we will increase wellness features and establish a full line-up. We will provide our customers with hyper-personalized experiences by applying generative AI technologies and secure core technologies for future growth areas such as XR, digital Health, and Digital Wallet. At the same time, we will strive to secure stronger profitability by enhancing resource allocation. Networks Seek to grow revenue through timely responses to major overseas businesses while also winning orders for new businesses and reinforce its technology leadership in core 5G chips and vRAN."

06:41 EDT Air Lease places leases for two Boeing 737-8 aircraft with LOT Polish Airlines - Air Lease Corporation (AL) announced long-term lease placements for two new Boeing (BA) 737-8 aircraft with LOT Polish Airlines. Both aircraft are scheduled to deliver to LOT in mid-2024, and will add to the 11 Boeing 737-8s and one 787-9 Dreamliner aircraft already on lease from ALC.

06:38 EDT Samsung to seek qualitative growth in S.LSI segment in 2024 - The company said, "S.LSI: Expecting the mobile market to increase centering on premium products, we will seek qualitative growth by increasing our sales portion of flagship products. Meanwhile, we remain committed to ensuring a solid business structure by expanding our business area beyond the mobile market. Foundry The market is forecast to shift to growth thanks to a rebound in mobile demand and continued growth in HPC demand. We will strengthen our technology competitiveness through the 2H mass production of the 2nd generation 3-nano process as well as the 4th generation 4-nano process for HPC. For mature processes, we will strive to expand within applications such as HPC, automotives, consumer goods, etc., by developing specialized process technologies, including RF and eMRAM."

06:29 EDT Samsung plans to expand sales of advanced-node products in 2024 - The company said, "For PC and mobile, arrivals of some replacement cycles and continued growth in the high-density trend should boost demand; with the spread of on-device AI likely to provide additional momentum. In server, demand is forecast to recover gradually, driven by increased demand for AI and normalizing inventory levels at customers. However, we need to keep monitoring variables that affect server demand, such as changes in IT investments based on macro conditions, AI-orientated investments, and geopolitical issues. We will expand sales of advanced-node products, such as 1b-based DDR5/LPDDR5x and V8-based UFS 4.0; and we will actively address demand for generative AI by increasing our HBM3 and HBM3E portion of sales on the back of the largest production capacity in the industry."

06:25 EDT GE HealthCare reports Q3 cash flow from operating activities $650M - Cash flow from operating activities was $650M versus $622, up $28M year-over-year primarily due to strong inventory management. Free cash flow was $570M, up $22M year-over-year.

06:19 EDT Enterprise Products announces four new production projects in Permian Basin - Enterprise Products announced four new capital projects to support continuing production growth in the Permian Basin. The partnership has also begun initial steps to return the Seminole Pipeline, which has a capacity of 210,000 barrels per day of crude oil, to natural gas liquid transportation service in December. The four projects include two natural gas processing plants, the Bahia NGL pipeline, NGL fractionator 14 and an associated deisobutanizer at Enterprise's Chambers County, Texas complex. Each of these projects is expected to begin service during 2025. Enterprise's fundamentals group forecasts crude oil production in the Permian Basin is on track to increase by over 700,000 BPD in 2023 and to grow by approximately 1.5 million BPD for the three-year period ending 2025. Post 2025, the company expects crude oil production from the basin to reach in excess of 7.5 million BPD by the end of 2030. The partnership believes NGL production from the basin is on track to increase by over 200,000 BPD in 2023, and grow by 700,000 BPD for the three-year period ending 2025. From 2025 to 2030, Enterprise believes NGL production from the Permian could grow by over 500,000 BPD to nearly 4.0 million BPD by the end of 2030. Enterprise has started construction on the Mentone 4 natural gas plant serving the Delaware Basin. Mentone 4 will have the capacity to process over 300 MMcf/d of natural gas to extract more than 40,000 BPD of NGLs. This plant is expected to begin service in the second half of 2025. Upon the completion of Mentone 3 and Mentone 4, Enterprise will have approximately 2.5 Bcf/d of natural gas processing capacity in the Delaware Basin capable of extracting more than 330,000 BPD of NGLs. Enterprise has also commenced construction on the Orion natural gas processing plant. Orion will have the capacity to process over 300 MMcf/d of natural gas to extract more than 40,000 BPD of NGLs. This plant is expected to be in service in the second half of 2025. Construction of the previously announced Leonidas natural gas processing plant, which also has the capacity to process in excess of 300 MMcf/d of natural gas, is proceeding on schedule and is expected to begin service in 1Q24. Enterprise will build the Bahia NGL pipeline, a 550-mile pipeline with the capacity to transport up to 600,000 BPD of NGLs originating from the Delaware and Midland basins to Enterprise's fractionation complex in Chambers County. This pipeline, which is currently expected to be wholly owned by Enterprise, is projected to begin service in the first half of 2025. Enterprise has begun preparations to convert the Seminole Red Pipeline from crude oil service back to NGL service in December 2023. This pipeline has been in crude oil transportation service since 2Q19 and was known as Enterprise's Midland-to-ECHO 2 crude oil pipeline. Prior to 2019, the Seminole Red Pipeline was in NGL service. The final Permian growth project is Enterprise's NGL fractionator 14 in Chambers County. This plant will have the capacity to fractionate up to 195,000 BPD of NGLs and the new associated DIB unit will have the capability to separate up to 100,000 BPD of butanes. Construction is scheduled to be completed during the second half of 2025.

06:14 EDT Cognex raises quarterly dividend 7% to 7.5c per share - Payable on December 1 to all shareholders of record at the close of business on November 17.

06:09 EDT BP intends to execute further $1.5B share buyback - bp intends to execute a further $1.5B share buyback prior to reporting fourth quarter results. bp remains committed to using 60% of 2023 surplus cash flow for share buybacks, subject to maintaining a strong investment grade credit rating.

06:01 EDT Sensata CFO Paul Vasington to retire, Brian Roberts to succeed - Sensata announced that Brian Roberts has been named as Sensata's new CFO, beginning immediately following the filing of the 10-Q for the third quarter in early November. Roberts will assume leadership and oversight of all global financial activities of Sensata. Brian will succeed Sensata's current CFO, Paul Vasington, who has decided to retire from the company. Paul will remain with Sensata through a transition period and will remain as an advisor to Jeff Cote and Brian until April 2, 2024.

05:49 EDT Orgenesis withdraws proposed underwritten public offering - Orgenesis announced that it has withdrawn its previously announced proposed underwritten public offering of securities due to market conditions.

05:33 EDT Stellantis sees FY23 adjusted operating income margin double-digit - Sees FY23 industrial free cash flows positive.